Kliniken & Zentren

Über uns

>

Kliniken & Zentren

>

Pflege & Versorgung

>

Karriere

>

Aktuelles & Termine

>

Schriftenverzeichnis der Klinik für Gynäkologie und Geburtshilfe


M. P. Lux, C. Minartz, H. Müller-Huesmann, M. F. Sandor, S. Radeck-Knorre, A. S. Neubauer

Budget Impact of the Oncotype DX Breast Recurrence Score® Test in Patients with Early Primary Hormone-Receptor-Positive, HER2-Negative, Node-Positive (pN1) Breast Cancer in Germany.

Breast Care, 2023

https://doi.org/10.1159/000534096

 

M. P. Lux, M. Untch, H.-C. Kolberg, M. Friedrich, M. Thill, F. Schütz

Can We Still Afford Innovative Surgical Procedures?

A structure and process analysis of the cost coverage of surgical therapy for patients with breast cancer in Germany with health economic evaluation examples based on superparamagnetic marking.

CC BY-NC-ND 4.0 · Senologie - Zeitschrift für Mammadiagnostik und –therapie, 20(02): 141-150, 2023

DOI: 10.1055/a-2045-0609

 

R. Mahtani, A. Niyazov, K. Lewis, A. Rider, L. Massey, B. Arondekar, M. P. Lux

Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel.

Adv Ther, 40(1):331-348, 2023

doi: 10.1007/s12325-022-02302-2

 

Originalarbeiten als Co-Autor

 

R. Togawa, J. Hederer, M. Ragazzi, T. Bruckner, S. Fastner, C. Gomez, A. Hennigs, J. Nees, A. Pfob, F. Riedel, B. Schäfgen, A. Stieber, M. P. Lux, J. Heil, M. Golatta

Imaging of lumpectomy surface with large field-of-view confocal laser scanning microscopy 'Histolog® scanner' for breast margin assessment in comparison with conventional specimen radiography.

Breast, 68:194-200, 2023

doi: 10.1016/j.breast.2023.02.010

 

Morra A, Schreurs MAC, Andrulis IL, Anton-Culver H, Augustinsson A, Beckmann MW, Behrens S, Bojesen SE, Bolla MK, Brauch H, Broeks A, Buys SS, Camp NJ, Castelao JE, Cessna MH, Chang-Claude J, Chung WK; NBCS Collaborators; Colonna SV, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Dennis J, Devilee P, Dörk T, Dunning AM, Dwek M, Easton DF, Eccles DM, Eriksson M, Evans DG, Fasching PA, Fehm TN, Figueroa JD, Flyger H, Gabrielson M, Gago-Dominguez M, García-Closas M, García-Sáenz JA, Genkinger J, Grassmann F, Gündert M, Hahnen E, Haiman CA, Hamann U, Harrington PA, Hartikainen JM, Hoppe R, Hopper JL, Houlston RS, Howell A; ABCTB Investigators; kConFab Investigators; Jakubowska A, Janni W, Jernström H, John EM, Johnson N, Jones ME, Kristensen VN, Kurian AW, Lambrechts D, Le Marchand L, Lindblom A, Lubiński J, Lux MP, Mannermaa A, Mavroudis D, Mulligan AM, Muranen TA, Nevanlinna H, Nevelsteen I, Neven P, Newman WG, Obi N, Offit K, Olshan AF, Park-Simon TW, Patel AV, Peterlongo P, Phillips KA, Plaseska-Karanfilska D, Polley EC, Presneau N, Pylkäs K, Rack B, Radice P, Rashid MU, Rhenius V, Robson M, Romero A, Saloustros E, Sawyer EJ, Schmutzler RK, Schuetze S, Scott C, Shah M, Smichkkoska S, Southey MC, Tapper WJ, Teras LR, Tollenaar RAEM, Tomczyk K, Tomlinson I, Troester MA, Vachon CM, van Veen EM, Wang Q, Wendt C, Wildiers H, Winqvist R, Ziogas A, Hall P, Pharoah PDP, Adank MA, Hollestelle A, Schmidt MK, Hooning MJ

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.

Cancer Med, 12(15): 16142-16162, 2023

doi: 10.1002/cam4.6272

 

T. Engler, P. A. Fasching, D. Lüftner, A. D. Hartkopf, V. Müller, H. C. Kolberg, P. Hadji, H. Tesch, L. Häberle, J. Ettl, M. Wallwiener, M. W. Beckmann, A. Hein, E. Belleville, S. Uhrig, P. Wimberger, C. Hielscher, C. M. Kurbacher, R. Wuerstlein, M. Untch, F. A. Taran, H. M. Enzinger, P. Krabisch, M. Welslau, M. Maasberg, D. Hempel, M. P. Lux, L. L. Michel, W. Janni, D. Wallwiener, S. Y. Brucker, T. N. Fehm, A. Schneeweiss

Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT.

Senologie, 20 (01): 43-56, 2023

DOI: 10.1055/a-2008-6553

 

Morra A, Schreurs MAC, Andrulis IL, Anton-Culver H, Augustinsson A, Beckmann MW, Behrens S, Bojesen SE, Bolla MK, Brauch H, Broeks A, Buys SS, Camp NJ, Castelao JE, Cessna MH, Chang-Claude J, Chung WK; NBCS Collaborators; Colonna SV, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Dennis J, Devilee P, Dörk T, Dunning AM, Dwek M, Easton DF, Eccles DM, Eriksson M, Evans DG, Fasching PA, Fehm TN, Figueroa JD, Flyger H, Gabrielson M, Gago-Dominguez M, García-Closas M, García-Sáenz JA, Genkinger J, Grassmann F, Gündert M, Hahnen E, Haiman CA, Hamann U, Harrington PA, Hartikainen JM, Hoppe R, Hopper JL, Houlston RS, Howell A; ABCTB Investigators; kConFab Investigators; Jakubowska A, Janni W, Jernström H, John EM, Johnson N, Jones ME, Kristensen VN, Kurian AW, Lambrechts D, Le Marchand L, Lindblom A, Lubiński J, Lux MP, Mannermaa A, Mavroudis D, Mulligan AM, Muranen TA, Nevanlinna H, Nevelsteen I, Neven P, Newman WG, Obi N, Offit K, Olshan AF, Park-Simon TW, Patel AV, Peterlongo P, Phillips KA, Plaseska-Karanfilska D, Polley EC, Presneau N, Pylkäs K, Rack B, Radice P, Rashid MU, Rhenius V, Robson M, Romero A, Saloustros E, Sawyer EJ, Schmutzler RK, Schuetze S, Scott C, Shah M, Smichkkoska S, Southey MC, Tapper WJ, Teras LR, Tollenaar RAEM, Tomczyk K, Tomlinson I, Troester MA, Vachon CM, van Veen EM, Wang Q, Wendt C, Wildiers H, Winqvist R, Ziogas A, Hall P, Pharoah PDP, Adank MA, Hollestelle A, Schmidt MK, Hooning MJ

Res Sq, rs.3.rs-2569372, 2023

doi: 10.21203/rs.3.rs-2569372/v1. Preprint

 

Übersichtsarbeiten

 

M. P. Lux

Therapie des Hormonrezeptor-positiven/Her2-negativen Mammakarzinoms.

Forum Sanitas, 1: 6-8, 2024

 

M. Banys-Paluchowski, T. Kühn, Y. Masannat, I. Rubio, J. de Boniface, N. Ditsch, G. Karadeniz Cakmak, A. Karakatsanis, R. Dave, M. Hahn, S. Potter, A. Kothari, O. D. Gentilini, B. M. Gulluoglu, M. P. Lux, M. Smidt, W. P. Weber, B. Aktas Sezen, N. Krawczyk, S. Hartmann, R. Di Micco, S. Nietz, F. Malherbe, N. Cabioglu, N. Z. Canturk, M. L. Gasparri, D. Murawa, J. Harvey

Localization Techniques for Non-Palpable Breast Lesions: Current Status, Knowledge Gaps, and Rationale for the MELODY Study (EUBREAST-4/iBRA-NET, NCT 05559411).

Cancers (Basel), 15(4): 1173, 2023

doi: 10.3390/cancers15041173

 

M. Thill, C. Kolberg-Liedtke, U. S. Albert, M. Banys-Paluchowski, I. Bauerfeind, J. U. Blohmer, W. Budach, P. Dall, N. Ditsch, E. M. Fallenberg, P. A. Fasching, T. Fehm, M. Friedrich, B. Gerber, O. Gluz, N. Harbeck, A. D. Hartkopf, J. Heil, J. Huober, C. Jackisch, H. H. Kreipe, D. Krug, T. Kühn, S. Kümmel, S. Loibl, D. Lüftner, M. P. Lux, N. Maass, C. Mundhenke, T. Reimer, K. Rhiem, A. Rody, M. Schmidt, A. Schneeweiss, F. Schütz, H. P. Sinn, C. Solbach, E. F. Solomayer, E. Stickeler, C. Thomssen, M. Untch, I. Witzel, A. Wöckel, V. Müller, R. Würstlein, W. Janni, T. W. Park-Simon

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023.

Breast Care (Basel), 18(4): 306-315, 2023

doi: 10.1159/000531579

 

T. W. Park-Simon, V. Müller, C. Jackisch, U. S. Albert, M. Banys-Paluchowski, I. Bauerfeind, J. U. Blohmer, W. Budach, P. Dall, N. Ditsch, E. M. Fallenberg, P. A. Fasching, T. Fehm, M. Friedrich, B. Gerber, O. Gluz, N. Harbeck, A. D. Hartkopf, J. Heil, J. Huober, C. Kolberg-Liedtke, H. H. Kreipe, D. Krug, T. Kühn, S. Kümmel, S. Loibl, D. Lüftner, M. P. Lux, N. Maass, C. Mundhenke, T. Reimer, K. Rhiem, A. Rody, M. Schmidt, A. Schneeweiss, F. Schütz, H. P. Sinn, C. Solbach, E. F. Solomayer, E. Stickeler, C. Thomssen, M. Untch, I. Witzel, A. Wöckel, R. Wuerstlein, W. Janni, M. Thill

Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023.

Breast Care (Basel), 18(4):289-305, 2023

doi: 10.1159/000531578

 

D. Lüftner, M. P. Lux, T. N. Fehm, M. Welslau, V. Müller, F. Schütz, P. A. Fasching, W. Janni, C. Thomssen, I. Witzel, M. Beierlein, E. Belleville, M. Untch, M. Thill, N. Ditsch, B. Aktas, M. Banys-Paluchowski, C. Kolberg-Liedtke, A. Wöckel, H.-C. Kolberg, N. Harbeck, E. Stickeler, H. Tesch, A. D. Hartkopf

Update Mammakarzinom 2022 Teil 6 – Brustkrebs in fortgeschrittenen Krankheitsstadien.

Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer.

Senologie - Zeitschrift für Mammadiagnostik und –therapie, 20(02): 159-169, 2023

DOI: 10.1055/a-2079-8481

 

M. P. Lux, P. A. Fasching

Das Mammakarzinom und die genetische BRCA1/2-Testung in der klinischen Routine: warum, wann und für wen?

Geburtshilfe Frauenheilkd, 83: 310-321, 2023

 

H.-C. Kolberg, A. D. Hartkopf, T. N. Fehm, M. Welslau, V. Müller, F. Schütz, P. A. Fasching, W. Janni, I. Witzel, C. Thomssen, M. Beierlein, E. Belleville, M. Untch, M. Thill, H. Tesch, N. Ditsch, M. P. Lux, B. Aktas, M. Banys-Paluchowski, C. Kolberg-Liedtke, A. Wöckel, N. Harbeck, E. Stickeler, R. Bartsch, A. Schneeweiss, J. Ettl, D. Krug , F. –A. Taran, D. Lüftner, R. Würstlein

Update Mammakarzinom 2023 Teil 3 – Expertenmeinungen zu Brustkrebs in frühen Krankheitsstadien.

Senologie - Zeitschrift für Mammadiagnostik und –therapie, 20 (04): 330-339, 2023

DOI: 10.1055/a-2183-3169

 

M. P. Lux, A. Hartkopf, T. N. Fehm, M. Welslau, V. Müller, F. Schütz, P. A. Fasching, W. Janni, I. Witzel, C.  Thomssen, M. Beierlein, E. Belleville, M. Untch, M. Thill, H. Tesch, N. Ditsch, B. Aktas, M. Banys-Paluchowski, C.  Kolberg-Liedtke, A. Wöckel, H.-C. Kolberg, N. Harbeck, R. Bartsch, A. Schneeweiss, J. Ettl, R. Würstlein, D. Krug, F.-A. Taran, D. Lüftner, E. Stickeler

Update Mammakarzinom 2023 Teil 2 – Brustkrebs in fortgeschrittenen Krankheitsstadien.

Senologie - Zeitschrift für Mammadiagnostik und –therapie, 20(04): 320-329, 2023

DOI: 10.1055/a-2183-3490

 

M. P. Lux, P. A. Fasching

Das Mammakarzinom und die genetische BRCA1/2-Testung in der klinischen Routine: warum, wann und für wen?

Senologie - Zeitschrift für Mammadiagnostik und –therapie, 20(04): 292-302, 2023

DOI: 10.1055/a-2183-3310

 

D. Lüftner, M. P. Lux, T. N. Fehm, M. Welslau, V. Müller, F. Schütz, P. A. Fasching, W. Janni, C. Thomssen, I. Witzel, M. Beierlein, E. Belleville, M. Untch, M. Thill, N. Ditsch, B. Aktas, M. Banys-Paluchowski, C. Kolberg-Liedtke, A. Wöckel, H.-C. Kolberg, N. Harbeck, E. Stickeler, H. Tesch, A. D. Hartkopf

Update Mammakarzinom 2022 Teil 6 – Brustkrebs in fortgeschrittenen Krankheitsstadien.

Geburtshilfe Frauenheilkd,;83(3): 299-309, 2023

doi: 10.1055/a-2018-9184

 

T. N. Fehm, M. Welslau, V. Müller, D. Lüftner, F. Schütz, P. A. Fasching, W. Janni, C. Thomssen, I. Witzel, M. Beierlein, E. Belleville, M. Untch, M. Thill, H. Tesch, N. Ditsch, M. P. Lux, B. Aktas, M. Banys-Paluchowski, C. Kolberg-Liedtke, A. D. Hartkopf, A. Wöckel, H. C. Kolberg, N. Harbeck, E. Stickeler

Update Breast Cancer 2022 Part 5 - Early Stage Breast Cancer.

Geburtshilfe Frauenheilkd, 83(3): 289-298, 2023

doi: 10.1055/a-2018-9053

 

H.-C. Kolberg, A. D. Hartkopf, T. N. Fehm, M. Welslau, V. Müller, F. Schütz, P. A. Fasching, W. Janni, I. Witzel, C. Thomssen, M. Beierlein, E. Belleville, M. Untch, M. Thill, H. Tesch, N. Ditsch, M. P. Lux, B. Aktas, M. Banys-Paluchowski, C. Kolberg-Liedtke, A. Wöckel, N. Harbeck, E. Stickeler, R. Bartsch, A. Schneeweiss, J. Ettl, D. Krug , F. –A. Taran, D. Lüftner, R. Würstlein

Update Breast Cancer 2023 Part 3 - Expert Opinions of Early Stage Breast Cancer Therapies.

Geburtshilfe Frauenheilkd, 83(9): 1117-1126, 2023

doi: 10.1055/a-2143-8125

 

A. D. Hartkopf, T. N. Fehm, M. Welslau, V. Müller, F. Schütz, P. A. Fasching, W. Janni, I. Witzel, C. Thomssen, M. Beierlein, E. Belleville, M. Untch, M. Thill, H. Tesch, N. Ditsch, M. P. Lux, B. Aktas, M. Banys-Paluchowski, C. Kolberg-Liedtke, A. Wöckel, H.-C. Kolberg, N. Harbeck, E. Stickeler, R. Bartsch, A. Schneeweiss, J. Ettl, R. Würstlein, D. Krug, F.-A. Taran, D. Lüftner

Update Breast Cancer 2023 Part 1 – Early Stage Breast Cancer.

Geburtshilfe Frauenheilkd, 83 (06): 653-663, 2023

 

M. P. Lux, A. Hartkopf, T. N. Fehm, M. Welslau, V. Müller, F. Schütz, P. A. Fasching, W. Janni, I. Witzel, C.  Thomssen, M. Beierlein, E. Belleville, M. Untch, M. Thill, H. Tesch, N. Ditsch, B. Aktas, M. Banys-Paluchowski, C.  Kolberg-Liedtke, A. Wöckel, H.-C. Kolberg, N. Harbeck, R. Bartsch, A. Schneeweiss, J. Ettl, R. Würstlein, D. Krug, F.-A. Taran, D. Lüftner, E. Stickeler

Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer.

Geburtshilfe Frauenheilkd, 83 (06): 664-672, 2023

 

M. Banys-Paluchowski, M. Thill, T. Kühn, N. Ditsch, J. Heil, A. Wöckel, E. Fallenberg, M. Friedrich, S. Kümmel, V. Müller, W. Janni, U.-S. Albert, I. Bauerfeind, J.-U. Blohmer, W. Budach, P. Dall, P. A. Fasching, T. Fehm, O. Gluz, N. Harbeck, J. Huober, C. Jackisch, C. Kolberg-Liedtke, H. Kreipe, D. Krug, S. Loibl, D. Lüftner, M. P. Lux, N. Maass, C. Mundhenke, U. Nitz, T. W. Park-Simon, T. Reimer, K. Rhiem, A. Rody, M. Schmidt, A. Schneeweiss, F. Schütz, H. P. Sinn, C. Solbach, E.-F. Solomayer, E. Stickeler, C. Thomssen, M. Untch, I. Witzel, B. Gerber

AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022

AGO-Empfehlungen zur operativen Therapie des Mammakarzinoms: Update 2022

Senologie, 20(01): 81-93, 2023

 

B. Aktas, T. N. Fehm, M. Welslau, V. Müller, D. Lüftner, F. Schütz, P. A. Fasching, W. Janni, C. Thomssen, I. Witzel, E. Belleville, M. Untch, M. Thill, H. Tesch, N. Ditsch, M. P. Lux, M. Banys-Paluchowski, C. Kolberg-Liedtke, A. D. Hartkopf, A. Wöckel, H. –C. Kolberg, E. Stickeler, N. Harbeck, A. Schneeweiss

Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer.

Senologie, 20 (01): 70-80, 2023

DOI: 10.1055/a-2001-4729

 

Sonstige Artikel

 

F. Cardoso, F. Cognetti, M. P. Lux, A. Santaballa, R. Simcock, J. Wassermann, D. Bell, C. Biurrun, A. Di Leone, R. D´Antona, C. Degi, L. Guéroult-Accolas, I. Rubio

Awareness of Genomic Testing in Breast Cancer - A Call to Action Across Europe.

White Paper, Cancer Patients Europe, 2023

 

M. Banys-Paluchowski, M. P. Lux, M. Untch

Therapie beim HR+/Her2- metastasierten Brustkrebs.

AGO – State of the Art 2023.

Mamma Mia, Ausgabe 01: 12-13, 2024

 

M. P. Lux

Hoffnungsträger Her2-low.

Neue Therapieoptionen bei niedrig ausgeprägtem Her2-Rezeptoren.

PATH, Ausgabe 16: 16-17, 2023

 

Abstracts & Poster

 

M. Karthaus, D. C. Christoph, M. P. Lux, R.-D. Hofheinz, K. Jordan

Assessing the Benefit of NEPA (Fixed Combination of Netupitant/Palonosetron) for Preventing Chemotherapy-induced Nausea and Vomiting (CINV) in Patients at Increased Emetic Risk Receiving Moderately Emetogenic Chemotherapy.

Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 2023

 

M. Banys-Paluchowski, S. Hartmann, J. de Boniface, O. Gentilini, T. Basali, E. Stickeler, M. Untch, F. Ruf, S. Fröhlich, M. Thill, M. P. Lux, F. Peintinger, G. Karadeniz Cakmak, I. Rubio, M. Kontos, R. Di Micco, D. Murawa, E. Schlichting, B. Aktas Sezen, A. Rody, D. Langanke, N. Bündgen, J. Sanchez-Mendez, R. Buss-Steidle, C. Mau, N. Buchmann, S. Riemer, M. Hansen, N. Ditsch, T. Kühn

Radar reflectors for marking of target lymph nodes in patients receiving neoadjuvant chemotherapy for breast cancer – a subgroup analysis of the prospective AXSANA - (EUBREAST-03) trial.

San Antonio Breast Cancer Symposium: PO3-23-03, 2023

 

M. Banys-Paluchowski, T. Kühn, Y. Masannat, N. Ditsch, A. Esgueva, N. Cabıoğlu, D. Murawa, N. Canturk, I. Rubio, J. de Boniface, A. Karakatsanis, R. Dave, S. Potter, A. Kothari, O. Gentilini, W. Weber, N. Krawczyk, S. Hartmann, G. Karadeniz Cakmak, M. Hahn, M. P. Lux, T. Tvedskov, L. Pankratjevaite, M. Kontos, F. Peintinger, A. Lowery, M. Smidt, L. Rebaza, M. Vasconcelos, B. Gulluoglu, B. Aktas Sezen, R. Di Micco, S. Nietz, F. Malherbe, M. Gasparri, S. Alran, S. Deo, M. Khan, J. Harvey

MELODY: A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (EUBREAST-4 / iBRA-NET, NCT 05559411).

San Antonio Breast Cancer Symposium: PO4-18-12, 2023

 

H. Kolberg, J. Schumacher, R. Erber, M. Braun, P. Fasching, E. Grischke, C. Schem, M. P. Lux, M. Deryal, O. Hoffmann, B. Heinrich, G. Kunz, K. Lübbe, P. Krabisch, A. Hartmann, P. Raeth, S. Kasimir-Bauer, C. Kolberg-Liedtke

Comparison of an Atezolizumab monotherapy window followed by Atezolizumab and chemotherapy vs. Atezolizumab and chemotherapy alone in triple negative breast cancer (TNBC) – final analysis of the neoadjuvant neoMono trial.

San Antonio Breast Cancer Symposium: PS16-01, 2023

 

A. Cardone, D. Bell, C. B. Biurrun, F. Cardoso, L. D. Csaba, L. Guéroult-Accolas, M. P. Lux, A. Ramírez Piris, I. Rubio, R. Simcock, R. D’Antona Fidanzia

Awareness of genomic testing among patients with breast cancer in Europe.

Annals of Oncology, 34 (Supplement 2): S311, 2023

 

J. C. Radosa, T. Fietz, J. Wilke, T. Decker, V. Petersen, M. Deryal, J. Knoblich, C. Losem, U. Rhein, B. Schöttker, D. Wrobel, G. Pfeiler, E. Zanucco, J. Buncke, S. Woerner, K. Gratzke, A. Adams, E. Glastetter, R. Bartsch, M. P. Lux,

Palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer patients: Interim results of the PERFORM study.

Annals of Oncology, 34 (Supplement 2): S353-S354, 2023

 

S. Seidel, M. Pazos, S. Kümmel, S. Brandner, J. Tio, S. Seitz, M. Thill, M. P. Lux, M. Braun, P. Wülfing, J. Wolff, F. Horn, A. Seitz, N. Harbeck, R. Würstlein

Effekte auf die psychische Belastung bei Brustkrebspatient*innen durch altersbedingte Nutzungsunterschiede der PINK! Coach App.

Geburtshilfe und Frauenheilkunde, 83: 742, 2023

 

R. Erber, H.-C. Kolberg, J. Schumacher, M. Braun, P. A. Fasching, E.-M. Grischke, C. Schem, M. P. Lux, M. Deryal, O. Hoffmann, B. Heinrich, G. Kunz, K. Luebbe, P. Krabisch, A. Hartmann, P. Raeth, S. Kasimir-Bauer, C. Kolberg-Liedtke

Association between pCR, TILs, and Ki-67 at baseline and after 2 weeks in patients with triple-negative breast cancer (TNBC) treated with atezolizumab and chemotherapy +/- a preceding atezolizumab monotherapy window: A translational analysis of the neoMono trial.

ASCO Annual Meeting, 2023

J Clin Oncol, 41: suppl 16 (abstr 595), 2023

 

M. Banys-Paluchowski, T. Kühn, Y. Masannat, I. T. Rubio, J. de Boniface, N. Ditsch, A. Karakatsanis, R. V. Dave, S. Potter, A. Kothari, O. D. Gentilini, W. P. Weber, N. Krawczyk, S. Hartmann, G. K. Cakmak, M. Hahn, M. P. Lux, M. Smidt, N. Cabioglu, J. Harvey

MELODY (Methods for Localization of Different Types of Breast Lesions): A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (EUBREAST-4/iBRA-NET).

ASCO Annual Meeting, 2023

J Clin Oncol, 41: suppl 16 (abstr TPS626), 2023

 


Originalarbeiten als Erstautor oder Letztautor

R. Mahtani, A. Niyazov, K. Lewis, A. Rider, L. Massey, B. Arondekar, M. P. Lux

Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel.

Adv Ther, 2022

doi: 10.1007/s12325-022-02302-2. Online ahead of print.

 

 

M. F. Sandor, B. Schwalbach, V. Hofmann, S. E. Istrate, Z. Schuller, E. Ionescu, S. Heimann, M. Ragazzi, M. P. Lux

Imaging of lumpectomy surface with large field-of-view confocal laser scanning microscope for intraoperative margin assessment - POLARHIS study.

Breast, 66:118-125, 2022

doi: 10.1016/j.breast.2022.10.003. Epub 2022 Oct 5.

 

 

R. Mahtani, A. Niyazov, B. Arondekar, K. Lewis, A. Rider, L. Massey, M. P. Lux

BRCA1/2 Mutation Testing in Patients with HER2-Negative Advanced Breast Cancer: Real-World Data from the United States, Europe, and Israel.

Cancers (Basel), 14(21): 5399, 2022

Published online 2022 Nov 2. doi: 10.3390/cancers14215399

 

M. P. Lux, K. Lewis, A. Rider, A. Niyazov

Treatment patterns, Safety, and Patient Reported Outcomes among Adult Women with Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer with or without, or with Unkown, BRCA1/2 Mutation(s): Results of a Real-World Study from the United States, United Kingdom, and four EU countries.

Breast Care, 17: 460-469, 2022

 

 

M. P. Lux, K. Lewis, A. Rider, A. Niyazov

Real-world Multi-country Study of BRCA1/2 Mutation Testing Among Adult Women With HER2-Negative Advanced Breast Cancer.

Future Oncol, 18(9):1089-1101, 2022

doi: 10.2217/fon-2021-1387. Epub 2022 Jan 31.

 

R. Mahtani, A. Niyazov, B. Arondekar, K. Lewis, A. Rider, L. Massey, M. P. Lux

Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel.

BMC Cancer, 22(1): 1343, 2022

doi: 10.1186/s12885-022-10325-9.

 

R. Mahtani, A. Niyazov, B. Arondekar, K. Lewis, A. Rider, M. P. Lux

Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel.

Breast, 66:236-244, 2022

doi: 10.1016/j.breast.2022.10.009. Epub 2022 Oct 18

 

M. P. Lux, C. Minartz, H. Müller-Huesmann, M.-F. Sandor, K. H. Herrmann, S. Radeck-Knorre, A. S. Neubauer

Budget Impact of the Oncotype DX® Test compared to Other Gene Expression Tests in Patients with Early Breast Cancer in Germany.

Cancer Treat Res Commun, 31: 100519, 2022

doi: 10.1016/j.ctarc.2022.100519. Epub 2022 Jan 20.

 

M. P. Lux, T. Decker, E. D. Runkel, A. Niyazov, R. G. W. Queke, N. Marschner, N. Harbeck

Awareness and Availability of Routine Germline BRCA1/2 Mutation Testing in Patients With Advanced Breast Cancer in Germany.

Breast care, 17: 40-46, 2022

Originalarbeiten als Co-Autor

V. Müller, A. Hein, A. D. Hartkopf, P. A. Fasching, H. C. Kolberg, P. Hadji, H. Tesch, L. Häberle, J. Ettl, D. Lüftner, M. Wallwiener, M. W. Beckmann, A. Schneeweiss, E. Belleville, S. Uhrig, P. Wimberger, C. Hielscher, J. Meyer, L. A. Wurmthaler, C. M. Kurbacher, R. Wuerstlein, M. Untch, W. Janni, F. A. Taran, M. P. Lux, D. Wallwiener, S. Y. Brucker, T. N. Fehm, L. L. Michel

Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry.

Eur J Cancer, 172: 13-21, 2022

doi: 10.1016/j.ejca.2022.05.015. Epub 2022 Jun 18.

 

T. Engler, P. A. Fasching, D. Lüftner, A. D. Hartkopf, V. Müller, H. C. Kolberg, P. Hadji, H. Tesch, L. Häberle, J. Ettl, M. Wallwiener, M. W. Beckmann, A. Hein, E. Belleville, S. Uhrig, P. Wimberger, C. Hielscher, C. M. Kurbacher, R. Wuerstlein, M. Untch, F. A. Taran, H. M. Enzinger, P. Krabisch, M. Welslau, M. Maasberg, D. Hempel, M. P. Lux, L. L. Michel, W. Janni, D. Wallwiener, S. Y. Brucker, T. N. Fehm, A. Schneeweiss

Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT.

Geburtshilfe Frauenheilkd, 82(10): 1055-1067, 2022

doi: 10.1055/a-1880-0087. eCollection 2022

 

H. Huebner, M. Ruebner, C. Kurbacher, P. Hadji, A. D. Hartkopf, M. P. Lux, J. Huober, S. Uhrig, F. A. Taran, F. Overkamp, H. Tesch, L. Häberle, D. Lüftner, M. Wallwiener, V. Müller, M. W. Beckmann, A. Hein, E. Belleville, M. Untch, W. Janni, T. N. Fehm, H. C. Kolberg, D. Wallwiener, S. Y. Brucker, A. Schneeweiss, J. Ettl, P. A. Fasching, L. L. Michel

Return of individual genomic research results within the PRAEGNANT multicenter registry study.

Breast Cancer Res Treat, 2022

doi: 10.1007/s10549-022-06795-x. Online ahead of print.

 

S. Hartmann, T. Kühn, M. Hauptmann, E. Stickeler, M. Thill, M. P. Lux, S. Fröhlich, F. Ruf, S. Loibl, J.-U. Blohmer, H.-C. Kolberg, E. Thiemann, M. Weigel, C. Solbach, G. Kaltenecker, P. Paluchowski, M. G. Schrauder, S. Paepke, D. Watermann, M. Hahn, M. Hufnagel, J. Lefarth, M. Untch, M. Banys-Paluchowski

Axillstaging nach neoadjuvanter Chemotherapie bei initial nodal positivem Mammakarzinom in Deutschland – Erste Ergebnisse aus der AXSANA-Studie.

Senologie, 19: 344-352, 2022

 

S. Hartmann, T. Kühn, M. Hauptmann, E. Stickeler, M. Thill, M. P. Lux, S. Fröhlich, F. Ruf, S. Loibl, J.-U. Blohmer, H.-C. Kolberg, E. Thiemann, M. Weigel, C. Solbach, G. Kaltenecker, P. Paluchowski, M. G. Schrauder, S. Paepke, D. Watermann, M. Hahn, M. Hufnagel, J. Lefarth, M. Untch, M. Banys-Paluchowski, the AXSANA Study Group.

Axillary Staging after Neoadjuvant Chemotherapy for Initially Node-Positive Breast Carcinoma in Germany: Initial Data from the AXSANA study.

Geburtshilfe Frauenheilkd, 82(9): 932-940, 2022

doi: 10.1055/a-1889-7883. eCollection 2022 Sep.

 

R. Erber, M. Angeloni, R. Stöhr, M. P. Lux, D. U. Gebauer, E. Pelz, A. Bankfalvi, K. W. Schmid, R. F. Walter, M. Vetter, C. Thomssen, D. Mayr, F. Klauschen, P. Sinn, K. Sotlar, K. Stering, A. Stenzinger, M. Wunderle, P. A. Fasching, M. W. Beckmann, O. Hoffmann, R. Kimmig, N. Harbeck, R. Wuerstlein, F. Ferrazzi, A. Hartmann

Molecular subtyping of invasive breast cancer using a PAM50-based multigene expression test – comparison with molecular-like subtyping by grading and immunohistochemistry and influence on oncologist’s decision on systemic therapy in a real-world setting.

Int J Mol Sci, 23(15): 8716, 2022

Published online 2022 Aug 5. doi: 10.3390/ijms23158716

 

N. Krawczyk, E. Ruckhäberle, M. P. Lux, T. Fehm, M. Greiling, M. Osygus

Ist die (neo-)adjuvante Therapie der Patientin mit einem Her2 positiven Mammakarzinom kostendeckend?

Prozesskostenanalyse der neoadjuvanten und postneoadjuvanten Systemtherapie von Patientinnen mit einem primären Her2 positiven Mammakarzinom.

Geburtshilfe Frauenheilkd, 2022

DOI 10.1055/a-1921-9336

 

Übersichtsarbeiten

M. Banys-Paluchowski, M. Thill, T. Kühn, N. Ditsch, J. Heil, A. Wöckel, E. Fallenberg, M. Friedrich, S. Kümmel, V. Müller, W. Janni, U.-S. Albert, I. Bauerfeind, J.-U. Blohmer, W. Budach, P. Dall, P. A. Fasching, T. Fehm, O. Gluz, N. Harbeck, J. Huober, C. Jackisch, C. Kolberg-Liedtke, H. Kreipe, D. Krug, S. Loibl, D. Lüftner, M. P. Lux, N. Maass, C. Mundhenke, U. Nitz, T. W. Park-Simon, T. Reimer, K. Rhiem, A. Rody, M. Schmidt, A. Schneeweiss, F. Schütz, H. P. Sinn, C. Solbach, E.-F. Solomayer, E. Stickeler, C. Thomssen, M. Untch, I. Witzel, B. Gerber

AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022

Geburtshilfe Frauenheilkd, 82: 1031-1043, 2022

 

M. P. Lux, E. D. Runkel, E. Glastetter, C. Vannier, J. Buncke, M. Frank, R. Bartsch, M. Thill, A. Wöckel

PERFORM: a non-interventional study assessing the patients’ treatment starting with 1L palbociclib in HR+/HER2- ABC.

Future Oncol, 10.2217/fon-2022-0552, 2022

 

T. N. Fehm, M. Welslau, V. Müller, D. Lüftner, F. Schütz, P. A. Fasching, C. Thomssen, I. Witzel, E. Belleville, M. Untch, M. Thill, H. Tesch, N. Ditsch, M. P. Lux, B. Aktas, M. Bany-Paluchowski, A. Schneeweiss, C. Kolberg-Liedtke, A. D. Hartkopf, A. Wöckel, H.C. Kolberg, N. Harbeck, E. Stickeler

Update Breast Cancer 2022 Part 3 – Early Stage Breast Cancer.

Geburtshilfe Frauenheilkd, 82(9): 912–921, 2022

Published online 2022 Sep 13. doi: 10.1055/a-1912-7105

 

B. Aktas, T. N. Fehm, M. Welslau, V. Müller, D. Lüftner, F. Schütz, P. A. Fasching, W. Janni, C. Thomssen, I. Witzel, E. Belleville, M. Untch, M. Thill, H. Tesch, N. Ditsch, M. P. Lux, M. Banys-Paluchowski, C. Kolberg-Liedtke, A. D. Hartkopf, A. Wöckel, H. –C. Kolberg, E. Stickeler, N. Harbeck, A. Schneeweiss

Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer.

Geburtshilfe Frauenheilkd, 82(9): 922–931, 2022

Published online 2022 Sep 13. doi: 10.1055/a-1912-7362

 

T. N. Fehm, M. Welslau, V. Müller, D. Lüftner, F. Schütz, P. A. Fasching, C. Thomssen, I. Witzel, E. Belleville, M. Untch, M. Thill, H. Tesch, N. Ditsch, M. P. Lux, B. Aktas, M. Bany-Paluchowski, A. Schneeweiss, C. Kolberg-Liedtke, A. D. Hartkopf, A. Wöckel, H.C. Kolberg, N. Harbeck, E. Stickeler

Update Breast Cancer 2022 Part 3 – Early Stage Breast Cancer.

Senologie,19: 365-375, 2022

 

V. Müller, M. Welslau, D. Lüftner, F. Schütz, E. Stickeler, P. A. Fasching, W. Janni, C. Thomssen, I. Witzel, T. N. Fehm, E. Belleville, S. Bader, K. Seitz, M. Untch, M. Thill, H. Tesch, N. Ditsch, M. P. Lux, B. Aktas, M. Banys-Paluchowski, A.Schneeweiss, N. Harbeck, R. Würstlein, A. D. Hartkopf, H.-C. Kolberg, A. Wöckel

Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer.

Senologie,19: 353-364, 2022

 

T. Engler, P. A. Fasching, D. Lüftner, A. D. Hartkopf, V. Müller, H.-C. Kolberg, P. Hadji, H. Tesch, L. Häberle, J. Ettl, M. Wallwiener, M. W. Beckmann, A. Hein, E. Belleville, S. Uhrig, P. Wimberger, C. Hiescher, C. M. Kurbacher, R. Würstlein, M. Untch, F.-A. Taran, H.-M. Enzinger, P. Krabisch, M. Welslau, M. Maasberg, D. Hempel, M. P. Lux, L. L. Michel, W. Janni, D. Wallwiener, S. Y. Brucker, T. N. fehm, A. Schneeweiss

Implementation of CDK4/6 Inhibitors and its influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT.

Geburtsh Frauenheilk, 82, 1055-1067, 2022

 

M. Thill, D. Lüftner, C. Kolberg-Liedtke, U.-S. Albert, M. Banys-Paluchowski, I. Bauerfeind, J.-U. Blohmer, W. Budach, P. Dall, E. M. Fallenberg, P. A. Fasching, T. Fehm, M. Friedrich, B. Gerber, O. Gluz, N. Harbeck, J. Heil, J. Huober, C.  Jackisch, H.-H. Kreipe, D. Krug, T. Kühn, S. Kümmel, S.  Loibl, M. P. Lux, N. Maass, C. Mundhenke, U. Nitz, T.-W. Park-Simon, T. Reimer, K. Rhiem, A. Rody, M. Schmidt, A. Schneeweiss, F. Schütz, H.-P. Sinn, C. Solbach, E.-F. Solomayer, E. Stickeler, C. Thomssen, M. Untch, I. Witzel, A. Wöckel, V. Müller, W. Janni, N. Ditsch

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022.

Breast Care, 17: 421-429, 2022

 

N. Ditsch, A. Wöckel, M. Untch, C. Jackisch, U.-S. Albert, M. Banys-Paluchowski, I. Bauerfeind, J.-U. Blohmer, W. Budach, P. Dall, E. M. Fallenberg, P. A. Fasching, T. Fehm, M. Friedrich, B. Gerber, O. Gluz, N. Harbeck, J. Heil, J. Huober, C.  Jackisch, H.-H. Kreipe, D. Krug, T. Kühn, S. Kümmel, C. Kolberg-Liedtke, S.  Loibl, D. Lüftner, M. P. Lux, N. Maass, C. Mundhenke, U. Nitz, T.-W. Park-Simon, T. Reimer, K. Rhiem, A. Rody, M. Schmidt, A. Schneeweiss, F. Schütz, H.-P. Sinn, C. Solbach, E.-F. Solomayer, E. Stickeler, C. Thomssen, M. Untch, I. Witzel, V. Müller, W. Janni, M. Thill

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022.

Breast Care, 17: 403-420, 2022

 

C. Thomssen, T. N. Fehm, E. Stickeler, P. A. Fasching, W. Janni, C. Kolberg-Liedtke, H.-C. Kolberg, D. Lüftner, V. Müller, F. Schütz, E. Belleville, S. Bader, M. Untch, M. Welslau, M. Thill, A. D. Hartkopf, H. Tesch, N. Ditsch, M. P. Lux, A. Wöckel, B. Aktas, A. Schneeweiss, R. Würstlein

Update Mammakarzinom 2021 Teil 4 – Prävention und frühe Krankheitsstadien.

Senologie, 19: 175-184, 2022

 

M. Welslau, V. Müller, D. Lüftner, F. Schütz, E. Stickeler, P. A. Fasching, W. Janni, C. Thomssen, I. Witzel, T. N. Fehm, E. Belleville, S. Bader, K. Seitz, M. Untch, M. Thill, H. Tesch, N. Ditsch, M. P. Lux, B. Aktas, M. Banyse-Paluchowski, A.Schneeweiss, N. Harbeck, R. Würstlein, A. D. Hartkopf, A. Wöckel, B. Seliger, C. Massa, H.-C. Kolberg

Update Breast Cancer 2022 Part 1 – Early Stage Breast Cancer.

Geburtsh Frauenheihk, 82: 580-589, 2022

 

V. Müller, M. Welslau, D. Lüftner, F. Schütz, E. Stickeler, P. A. Fasching, W. Janni, C. Thomssen, I. Witzel, T. N. Fehm, E. Belleville, S. Bader, K. Seitz, M. Untch, M. Thill, H. Tesch, N. Ditsch, M. P. Lux, B. Aktas, M. Banys-Paluchowski, A.Schneeweiss, N. Harbeck, R. Würstlein, A. D. Hartkopf, H.-C. Kolberg, A. Wöckel

Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer.

Geburtsh Frauenheihk, 82: 590-600, 2022

 

N. Ditsch, E. Stickeler, A. Behrens, E. Belleville, P. A. Fasching, T. N. Fehm, A. D. Hartkopf, C. Jackisch, W. Janni, C. Kolberg-Liedtke, H.-C. Kolberg, D. Lüftner, M. P. Lux, V. Müller, A. Schneeweiss, F. Schütz, C. E. Schulmeyer, H. Tesch, C. Thomssen, C. Uleer, M. Untch, M. Welslau, A. Wöckel, L. A. Wurmthaler, R. Würstlein, M. Thill, B. Aktas

Update Mammaakarzinom 2021 Teil 2 – fortgeschrittene Stadien, Langzeitfolgen und Biomarker.

Senologie, 19: 65-74, 2022

 

M. Friedrich, T. Kühn, W. Janni, V. Müller, M. Banys-Pachulowski, C. Kolberg-Liedtke, C. Jackisch, D. Krug, U.-S. Albert, I. Bauerfeind, J. Blohmer, W. Budach, P. Dall, E. M. Fallenberg, P. A. Fasching, T. Fehm, B. Gerber, O. Gluz, V. Hanf, N. Harbeck, J. Heil, J. Huober, H.-H. Kreipe, S. Kümmel, S. Loibl, D. Lüftner, M. P. Lux, N. Maass, V. Möbus, C. Mundhenke, U. Nitz, T.-W. Park-Simon, T. Reimer, K. Rhiem, A. Rody, M. Schmidt, A. Schneeweiss, F. Schütz, H.-P. Sinn, C. Solbach, E-F. Solomayer, E. Stickeler, C. Thomssen, M. Untch, I. Witzel, A. Wöckel, M. Thill, N. Ditsch

AGO Empfehlungen zur operative Therapie der Axilla nach neoadjuvanter Chemotherapie: Update 2021

Senologie, 19: 56-64, 2022

 

C. Thomssen, T. N. Fehm, E. Stickeler, P. A. Fasching, W. Janni, C. Kolberg-Liedtke, H.-C. Kolberg, D. Lüftner, V. Müller, F. Schütz, E. Belleville, S. Bader, M. Untch, M. Welslau, M. Thill, A. D. Hartkopf, H. Tesch, N. Ditsch, M. P. Lux, A. Wöckel, B. Aktas, A. Schneeweiss, R. Würstlein

Update Breast Cancer 2021 Part 4 – Prevention and early stage disease.

Geburtshilfe Frauenheilkd, 82(2): 206–214, 2022

Published online 2022 Feb 11. doi: 10.1055/a-1724-9639

 

D. Lüftner, F. Schütz, E. Stickeler, P. A. Fasching, W. Janni, C. Kolberg-Liedtke, H.-C. Kolberg, C. Thomssen, V. Müller, T. N. Fehm, E. Belleville, S. Bader, M. Untch, M. Welslau, M. Thill, H. Tesch, N. Ditsch, M. P. Lux, A.

Wöckel, B. Aktas, A. Schneeweiss, R. Würstlein, A. D. Hartkopf

Update Breast Cancer 2021 Part 5 – Advanced stage disease.

Geburtshilfe Frauenheilkd, 82(2): 215-225, 2022

doi: 10.1055/a-1724-9569. eCollection 2022 Feb.

 

M. P. Lux, H. Lehmann, C. Maihöfner, R. Baron

Diagnose und Therapie der Chemotherapie-induzierten Polyneuropathie (CIPN)

Eine praktische Hilfe für den klinischen Alltag

VNR: 2760909011676990019, 2022

 

Case Reports

B. Klencsár, C. Schmücker, M. P. Lux

Uterusdurchbruch nach Perforation.

Frauenarzt, 7: 204, 2022

 

Sonstige Artikel

M. P. Lux, M. Schmidt, F. Schütz, I. Witzel

Therapie beim metastasierten Brustkrebs.

www.mammamia-online.de, Oktober bis Dezember, 2022

 

M. P. Lux

Welche neuen Therapien werden bald im klinischen Alltag eingesetzt werden können?

Top News aus San Antonio 2021 und Chicago 2022.

Newsletter PATH, Ausgabe 15, 2022

 

M. P. Lux

„Kein Brustkrebs gleicht dem anderen.“

inpact – Beilage Magazin Stern, Juli 2022

 

 

Abstracts & Poster

B. C. Teixeira, A. Rider, T. Holbrook, J. Piercy, M. P. Lux

Overall cancer survival inequalities in the state of São Paulo: A comparison between public and private systems.

ASCO Annual Meeting, 2022

M. P. Lux, L. Flöther, K. Frömter, B. Rack, K. Veselinovic, M. Heine, S. Paepke, P. Krabisch, T. S. Quandel, R. Sabatowski

Topical treatment of chemotherapy-induced peripheral Neuropathy (CIPN) with high concentration capsaicin in breast cancer patients - first interim analysis of the QUCIP study.

Topische Therapie der Chemotherapie-induzierten peripheren Neuropathie (CIPN) mit hochdosiertem Capsaicin bei Brustkrebspatientinnen - Erste Interimsanalyse der QUCIP-Studie.

DGHO Jahrestagung 2022

Oncol Res Treat, 45 (suppl 2): 139, 2022

 

T. Fietz, J. Wilke, M. Deryal, T. Gabrysiak, B. Schöttker, L. Jacobasch, V. Petersen, M. Weigel, D. Wrobel, E. Glastetter, L. Berger, M. Frank, S. M. Woerner, A. Adams, A. Wöckel, M. P. Lux

Erste Zwischenergebnisse der PERFORM-Studie zur Bewertung der endokrin-basierten Palbociclib-Erstlinientherapie für Patient:innen mit HR+/ HER2-fortgeschrittenem Brustkrebs in der Real World.

DGHO Jahrestagung 2022

Oncol Res Treat, 45 (suppl 2): 108, 2022

M. P. Lux, L. Flöther, C. Frömter, B. Rack, K. Veselinovic, M. Heine, S. Paepke, P. Krabisch, M. Bielzer, A. Holtdirk, T. Kottmann, T. S. Quandel, R. Sabatowski

Topische Therapie der Chemotherapie-induzierten peripheren Neuropathie (CIPN) mit hochdosiertem Capsaicin (179 mg) bei Mammakarzinompatientinnen – Erste Interimsanalyse der QUCIP-Studie.

Geburtsh Frauenheilk, 82: e121, 2022

DOI 10.1055/s-0042-1756942

 

H. –C. Kolberg, J. Schumacher, R. Erber, M. Braun, B. Heinrich, O. Hoffmann, P. A. Fasching, G. Kunz, M. P. Lux, C. Schem, E.-M. Grischke, M. Deryal, K. Lübbe, A. Hartmann, S. Kasimir-Bauer, C. Kolberg-Liedtke

Comparison of a mono Atezolizumab window followed by Atezolizumab and chemotherapy with Atezolizumab and chemotherapy in triple negative breast cancer – an interim analysis of the adaptive randomized neoadjuvant trial NeoMono.

SABCS, PD11-03, 2022

 

M.-F. Sandor, B. Schwalbach, V. Hofmann, S.-E. Istrate, Z. Schuller, E. Ionescu, M. Ragazzi, M.P. Lux

Imaging of lumpectomy surface with large field-of-view confocal laser scanning microscope ‘Histolog®​ Scanner’ for breast margin assessment in comparison with intraoperative imaging.

41. Jahrestagung der DGS e.V.

Senologie - Zeitschrift für Mammadiagnostik und –therapie, 19 (02): e36, 2022

 

M. P. Lux, J. Wilke, M. Deryal, T. Fietz, B. Schöttker, L. Jacobasch, V. Petersen, M. Weigel, D. Wrobel, E. Glastetter, L. Berger, M. Frank, S.M. Woerner, A. Adams, A. Wöckel

First interim results of the PERFORM study evaluating palbociclib in combination with endocrine therapy for HR+/HER2- advanced breast cancer.

41. Jahrestagung der DGS e.V.

Senologie - Zeitschrift für Mammadiagnostik und –therapie, 19 (02): e26-e27, 2022

 

M. P. Lux, C. Minartz, H. Müller-Huesmann, M.-F. Sandor, S. Radeck-Knorre, A.S Neubauer

Budget Impact des Oncotype DX Breast Recurrence Score®​ Tests bei Patientinnen mit einem primären Hormonrezeptor-positiven, HER2/neu-negativen, nodal-positiven und nicht metastasierten Mammakarzinom.

41. Jahrestagung der DGS e.V.

Senologie - Zeitschrift für Mammadiagnostik und –therapie, 19 (02): e26, 2022

 

M. P. Lux, M. Untch, H.-C. Kolberg, M. Friedrich, M. Thill, F. Schütz

Können innovative OP-Verfahren bei Patientinnen mit einem Mammakarzinom noch kostendeckend durchgeführt werden? Eine Struktur- und Prozessanalyse zur operativen Therapie des Mammakarzinoms in Deutschland.

41. Jahrestagung der DGS e.V.

Senologie - Zeitschrift für Mammadiagnostik und –therapie, 19 (02): e25-e26, 2022

 

B. Casaes Teixeira, A. Rider, T. Holbrook, J. Piercy, M. P. Lux

Overall cancer survival inequalities in the state of Sao Paulo: A comparison between public and private systems.

ASCO 2022

J Clin Oncol, 40 (suppl 16): abstr 6525, 2022


Originalarbeiten als Erstautor oder Letztautor

M. P. Lux, K. Lewis, A. Rider, A. Niyazov

BRCA1/2 mutation status, treatment patterns, safety, and patient-reported outcomes among adult women with human epidermal growth factor receptor 2–negative advanced breast cancer: Results of a real-world study from the United States, United Kingdom, and four EU countries.

Breast Care (in press), 2021

 

M. P. Lux, K. Lewis, A. Rider, A. Niyazov

Real-world Multi-country Study of BRCA1/2 Mutation Testing Among Adult Women With HER2-Negative Advanced Breast Cancer.

Future Oncology (Epub ahead of print), 2021

 

M. P. Lux, C. Minartz, H. Müller-Huesmann, M.-F. Sandor, K. H. Herrmann, S. Radeck-Knorre, A. S. Neubauer 

Budget Impact of the Oncotype DX® Test compared to Other Gene Expression Tests in Patients with Early Breast Cancer in Germany.

Cancer Treatment and Research Communications (in press), 2021

 

S. M. Jud, A. Brendle-Behnisch, C. Rauh, M. G. Schrauder, C. C. Hack, A.-L. Brandl, S. Wasner, C. Preuß, M. W. Beckmann, M. P. Lux  

Macromastia – an economic burden? A disease cost analysis based on real world data in Germany.

Archives of Gynecology and Obstetrics, 303(2): 521-531, 2021

 

Originalarbeiten als Co-Autor

P. A. Fasching, S. Yadav, C. Hu, M. Wunderle, L. Häberle, S. N. Hart, M. Rübner, E. C. Polley, K. Y. Lee, R. D. Gnanaolivu, P. Hadji, H. Hübner, H. Tesch, J. Ettl, F. Overkamp, M. P. Lux, A. B. Ekici, B. Volz, S. Uhrig, D. Lüftner, M. Wallwiener, V. Müller, E. Belleville, M. Untch, H.-C. Kolberg, M. W. Beckmann, A. Reis, A. Hartmann, W. Janni, P. Wimberger, F. A. Taran, T. N. Fehm, D. Wallwiener, S. Y. Brucker, A. Schneeweiss, A. D. Hartkopf, F. J. Couch

Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis.

J Clin Oncol, JCO2001200, 2021

doi: 10.1200/JCO.20.01200. Online ahead of print.

 

Übersichtsarbeiten

 

C. Thomssen, T. N. Fehm, E. Stickeler, P. A. Fasching, W. Janni, C. Kolberg-Liedtke, H.-C. Kolberg, D. Lüftner, V. Müller, F. Schütz, E. Belleville, S. Bader, M. Untch, M. Welslau, M. Thill, A. D. Hartkopf, H. Tesch, N. Ditsch, M. P. Lux, A. Wöckel, B. Aktas, A. Schneeweiss, R. Würstlein

Update Breast Cancer 2021 Part 4 – Prevention and early stage disease.

Geburtsh Frauenheilkd, 82: 206-214

 

D. Lüftner, F. Schütz, E. Stickeler, P. A. Fasching, W. Janni, C. Kolberg-Liedtke, H.-C. Kolberg, C. Thomssen, V. Müller, T. N. Fehm, E. Belleville, S. Bader, M. Untch, M. Welslau, M. Thill, H. Tesch, N. Ditsch, M. P. Lux, A. Wöckel, B. Aktas, A. Schneeweiss, R. Würstlein, A. D. Hartkopf

Update Breast Cancer 2021 Part 5 – Advanced stage disease.

Geburtsh Frauenheilkd, 82: 215-225

 

M. P. Lux, H. Lehmann, C. Maihöfner, R. Baron

Diagnose und Therapie der Chemotherapie-induzierten Polyneuropathie (CIPN) -

Eine praktische Hilfe für den klinischen Alltag.

(in press), 2021

 

M. P. Lux, O. Ciani, W. C. N. Dunlop, A. Ferris, M. Friedlander 

The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?

Cancer Manag Res, 13: 8457–8471, 2021 

doi: 10.2147/CMAR.S328058

 

N. Ditsch, E. Stickeler, A. Behrens, E. Belleville, P. A. Fasching, T. N. Fehm, A. D. Hartkopf, C. Jackisch, W. Janni, C. Kolberg-Liedtke, H.-C. Kolberg, D. Lüftner, M. P. Lux, V. Müller, A. Schneeweiss, F. Schütz, C. E. Schulmeyer, H. Tesch, C. Thomssen, C. Uleer, M. Untch, M. Welslau, A. Wöckel, L. A. Wurmthaler, R. Würstlein, M. Thill, B. Aktas

Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers.

Geburtsh Frauenheilkd, 81(5): 539–548, 2021

doi: 10.1055/a-1464-1221

 

A. Schneeweiss, P. A. Fasching, T. Fehm, B. Gerber, C. Jackisch, S. Loibl, M. Schmidt, E. Stickeler, A. Wöckel, W. Janni, V. Müller, on behalf of the AGO Kommission Mamma

AGO Algorithmen zur Behandlung von Brustkrebs: Update 2021.

Senologie, 18: 391-401, 2021

 

E. Stickeler, B. Aktas, A. Behrens, E. Belleville, N. Ditsch, P. A. Fasching, T. N.Fehm, A. D. Hartkopf, C. Jackisch, W. Janni, C. Kolberg-Liedtke, H.-C- Kolberg, D. Lüftner, M. P. Lux, V. Müller, A. Schneeweiss, F. Schütz, C. E. Schulmeyer, H. Tesch, C. Thomssen, C. Uleer, M. Untch, M. Welslau, A. Wöckel, L. A. Wurmthaler, R. Würstlein, M. Thill

Update Mammakarzinom 2021 Teil 1- Prävention und frühe Krankheitsstadien.

Senologie, 18: 377 - 390, 2021

 

A. Schneeweiss, P. A. Fasching, T. Fehm, B. Gerber, C. Jackisch, S. Loibl, M. Schmidt, E. Stickeler, A. Wöckel, W. Janni, V. Müller, on behalf of the AGO Kommission Mamma

AGO Algorithms for the Treatment of Breast Cancer: Update 2021.

Geburtsh Frauenheilk, 81: 1101–1111, 2021

 

M. Friedrich, T. Kühn, W. Janni, V. Müller, M. Banys-Pachulowski, C. Kolberg-Liedtke, C. Jackisch, D. Krug, U.-S. Albert, I. Bauerfeind, J. Blohmer, W. Budach, P. Dall, E. M. Fallenberg, P. A. Fasching, T. Fehm, B. Gerber, O. Gluz, V. Hanf, N. Harbeck, J. Heil, J. Huober, H.-H. Kreipe, S. Kümmel, S. Loibl, D. Lüftner, M. P. Lux, N. Maass, V. Möbus, C. Mundhenke, U. Nitz, T.-W. Park-Simon, T. Reimer, K. Rhiem, A. Rody, M. Schmidt, A. Schneeweiss, F. Schütz, H.-P. Sinn, C. Solbach, E-F. Solomayer, E. Stickeler, C. Thomssen, M. Untch, I. Witzel, A. Wöckel, M. Thill, N. Ditsch

AGO Recommendations for the Surgical Therapy of the Axilla - After Neoadjuvant Chemotherapy: 2021 Update.

Geburtsh Frauenheilk, 81: 1112–1120, 2021

 

M. P. Lux, A. Schneeweiss, A. D. Hartkopf, V. Müller, W. Janni, E. Belleville, E. Stickeler, M. Thill, P. A. Fasching, H.-C. Kolberg, M. Untch, N. Harbeck, A. Wöckel, C. Thomssen, C. E. Schulmeyer, M. Welslau, F. Overkamp, F. Schütz, D. Lüftner, N. Ditsch

Update Breast Cancer 2020 – Part V – Moving therapies from advanced to early breast cancer patients.

Senologie, 18: 254-265, 2021

 

N. Ditsch, C. Kolberg-Liedtke, M. Friedrich, C. Jackisch, U.-S. Albert, M. Banys-Paluchowski, I. Bauerfeind, J.-U. Blohmer, W. Budach, P. Dall. E. M. Fallenberg, P. A. Fasching, T. Fehm, B. Gerber, O. Gluz, N. Harbeck, J. Heil, J. Huober, C. Jackisch, H.-H. Kreipe, D. Krug, T. Kühn, S. Kümmel, S. Loibl, D. Lüftner D, M. P. Lux, N. Maass, C. A. Mundhenke, U. Nitz, T.-W. Park-Simon, T. Reimer, K. C. Rhiem, A. Rody, M. D. Schmidt, A. Schneeweiss, F. Schütz, H.-P. Sinn, C. Solbach, E.-F. Solomayer, E. K. Stickeler, C. Thomssen, M. Untch, I. Witzel, A. Wöckel, V. Müller, W. Janni, M. Thill

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021.

Breast Care, 16: 214-227, 2021

doi.org/10.1159/000516429

 

M. Thill, M. Friedrich, C. Kolberg-Liedtke, U.-S. Albert, M. Banys-Paluchowski, I. Bauerfeind, J.-U. Blohmer, W. Budach, P. Dall. E. M. Fallenberg, P. A. Fasching, T. Fehm, B. Gerber, O. Gluz, N. Harbeck, J. Heil, J. Huober, C. Jackisch, H.-H. Kreipe, D. Krug, T. Kühn, S. Kümmel, S. Loibl, D. Lüftner D, M. P. Lux, N. Maass, C. A. Mundhenke, U. Nitz, T.-W. Park-Simon, T. Reimer, K. C. Rhiem, A. Rody, M. D. Schmidt, A. Schneeweiss, F. Schütz, H.-P. Sinn, C. Solbach, E.-F. Solomayer, E. K. Stickeler, C. Thomssen, M. Untch, I. Witzel, A. Wöckel, V. Müller, W. Janni, N. Ditsch

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021.

Breast Care, 16: 228-235, 2021

doi.org/10.1159/000516420

 

D. Lüftner, A. D. Hartkopf, M. P. Lux, F. Overkamp, H. Tesch, A. Titzmann, P. Pöschke, M. Wallwiener, V. Müller, M. W. Beckmann, E. Belleville, W. Janni, T. N. Fehm, H.-C. Kolberg, J. Ettl., D. Wallwiener, A. Schneeweiss, S. Y. Brucker, P. A. Fasching

Challenges and Opportunities for Real-World Evidence in metastatic Luminal Breast Cancer. 

Breast Care, 16: 108-114, 2021 

 

M. P. Lux, A. Schneeweiss, A. D. Hartkopf, V. Müller, W. Janni, E. Belleville, E. Stickeler, M. Thill, P. A. Fasching, H.-C. Kolberg, M. Untch, N. Harbeck, A. Wöckel, C. Thomssen, C. E. Schulmeyer, M. Welslau, F. Overkamp, F. Schütz, D. Lüftner, N. Ditsch

Update Breast Cancer 2020 – Part V – Moving therapies from advanced to early breast cancer patients.

Geburtshilfe Frauenheilk, 81(4): 469-480, 2021 

 

H. Tesch, V. Müller, A. Wöckel, E. Ettl, E. Belleville, F. Schütz, A. Hartkopf, M. Thill, J, Huober, P. A. Fasching, H.-C. Kolberg, C. E. Schulmeyer, M. Welslau, F. Overkamp, T. N. Fehm, M. P. Lux, A. Schneeweiss, D. Lüftner, W. Janni

Update Breast Cancer 2020 – Part V – Advanced Breast Cancer.

Senologie, 18: 49-57, 2021

 

J. Huober, A. Schneeweiss, A. D. Hartkopf, V. Müller, M. P. Lux, W. Janni, J. Ettl, E. Belleville, M. Thill, P. A. Fasching, H. C. Kolberg, C. E. Schulmeyer, M. Welslau, F. Overkamp, H. Tesch, T. N. Fehm, D. Lüftner, F. Schütz, A. Wöckel

Update Breast Cancer 2020 – Part III – Early breast cancer.

Senologie, 18: 39-48, 2021

 

Buchkapitel/ Bücher

 

M. P. Lux, D. Lüftner, D. T. Schneider

Late Effects in Young Breast Cancer Survivor.

In J. D. Beck, C. Bokemeyer, T. Langer 

Late Treatment Effects and Cancer Survivor Care in the Young.

Springer, 2021, pp 357-364 

 

M. P. Lux, A. Hartmann

B3-Läsionen der Mamma.

In T. Fehm, P. Hadji, A. Rody, E. Solomayer

Gynäkologie konkret

Georg Thieme Verlag KG, Stuttgart, 2021

(ISBN 978-3-13-240257-7)

 

M. P. Lux, A. Hartmann

LCIS.

In T. Fehm, P. Hadji, A. Rody, E. Solomayer

Gynäkologie konkret

Georg Thieme Verlag KG, Stuttgart, 2021

(ISBN 978-3-13-240257-7)

 

M. P. Lux, A. Hartmann

M. Paget. 

In T. Fehm, P. Hadji, A. Rody, E. Solomayer

Gynäkologie konkret

Georg Thieme Verlag KG, Stuttgart, 2021

(ISBN 978-3-13-240257-7)

 

M. P. Lux, A. Hartmann

DCIS.

In T. Fehm, P. Hadji, A. Rody, E. Solomayer

Gynäkologie konkret

Georg Thieme Verlag KG, Stuttgart, 2021

(ISBN 978-3-13-240257-7)

 

Sonstige Artikel

 

M. P. Lux

„Was nun, Herr Professor Lux?“ – Rücknahme des neuen Medikaments Alpelisib

Newsletter PATH, Ausgabe 14, 20-21, 2021

 

Abstracts & Poster

 

S. Paepke, M. F. Sandor, M. P. Lux, M. Golatta

Utilization of confocal imaging for intraoperative margin assessment.

London Breast Meeting (LBM), 2021

 

F. Sandor, V. Hofmann, E. Ionescu, B. Schwalbach, M. P. Lux

Imaging of Lumpectomy Surface with Large Field-of-View Confocal Laser Scanning Microscope ‘Histolog® Scanner’ for Breast Margin Assessment in comparison with Intraoperative Imaging.

40th European Society of Surgical Oncology (ESSO), 2021

 

M. P. Lux, C. Minartz, H. Müller-Huesmann, M. F.  Sandor, K. H. Herrmann, S.  Radeck-Knorre, A. S. Neubauer

Budget Impact des Oncotype DX® Tests im Vergleich zu anderen Genexpressionstests bei Patientinnen mit einem Mammakarzinom im Frühstadium in Deutschland

DOI 10.1055/s-0041-1730192

Senologie, 18 (57): e22–e23, 2021

doi 10.1055/s-0041-1730192

 

M. P. Lux, T. Resch, S. Fuxius, T.  Gabrysiak, E. Amann, J. Buncke, M. Frank, E. D. Runkel, M. Thill

PERFORM: An epidemiological, prospective cohort study for patients with HR+/HER2- advanced breast cancer reated 1st-line with an endocrine-based palbociclib combination therapy in real world in Germany and Austria

Senologie, 18 (58): e23, 2021

doi 10.1055/s-0041-1730193

 

P. A. Fasching, S. Y. Brucker, H. Tesch, D. Wallwiener, S. Uhrig, L. Häberle, M. Wallwiener, P. Hadji, T. N. Fehm, W. Janni, D. Lüftner, M. P. Lux, J. Ettl, A. Hartkopf, V. Müller, F. A. Taran, T. Spall, E. Belleville, A. Hein, A. Schneeweiss, H.-C. Kolberg, PRAEGNANT

Comparison of therapy benefit from standard anti-HER2-directed approaches in metastatic breast cancer (MBC) between initially HER2-positive patients and patients initially HER2-negative with switch to HER2-positive

Senologie, 18 (106): e45, 2021

doi 10.1055/s-0041-1730464

 

C. Kolberg-Liedtke, J. Schumacher, R. Erber, M. Braun, B. Heinrich, O. Hoffmann, P. A. Fasching, H. Forstbauer, A. Kleine-Tebbe, G. Kunz, M. P. Lux, J. Rom, C. Schem, N. Stahl, A. Hartmann, S. Kasimir-Bauer, H.-C. Kolberg, Phaon Scientific 

neoMono - An adaptive randomized neoadjuvant two arm trial in patients with TNBC comparing a mono atezolizumab window followed by atezolizumab and chemotherapy with atezolizumab and chemotherapy.

SABCS, OT2-29-01, 2021

 

H.-C. Kolberg, J. Schumacher, R. Erber, M. Braun, O. Hoffmann, C. Schem, H. Forstbauer, B. Heinrich, P. Staib, J. Rom, G. Kunz, A. Kleine-Tebbe, M. P. Lux, A. Heider, P. A. Fasching, A. Hartmann, S. Kasimir-Bauer, C. Kolberg-Liedtke

An adaptive randomized neoadjuvant two arm trial in triple-negative breast cancer (TNBC) comparing a mono Atezolizumab window followed by Atezolizumab and chemotherapy with Atezolizumab and chemotherapy (neoMono).

ESMO, 2021

 

H.-C. Kolberg, Ö. Yüksel, P. A. Fasching, S. Brucker, H. Tesch, D. Wallwiener, L. Haeberle, M. Wallwiener, P. Hadji, T. N. Fehm, W. Janni, D. Lüftner, M. P. Lux, J. Ettl, A. D. Hartkopf, V. Müller, F. –A. Taran, E. Belleville, A. Hein, A. Schneeweiss

Comparison of therapy benefit from standard anti-HER2 directed approaches in metastatic breast cancer (MBC) between initially HER2-positive patients and patients initially HER2-negative with switch to HER2-positive.

ASCO Annual Meeting 2021

J Clin Oncol 39 (suppl 15): abstr 1040, 2021

 

R. L. Mahtani, A. Niyazov, K. Lewis, L. Massey, A. Rider, B. Arondekar, M. P. Lux

Impact of race on biomarker testing among HER2- advanced breast cancer (ABC) patients (pts) in the United States: Results from a real-world study.

ASCO Annual Meeting 2021

J Clin Oncol 39 (suppl 15): abstr 10598, 2021

 

R. Mahtani, A. Niyazov, K. Lewis, A. Rider, B. Arondekar, M. P. Lux

Real-world Study of Patient Demographics, Clinical Characteristics, and BRCA1/2 Testing in HER2-negative (HER2–) Advanced Breast Cancer (ABC) in the US and Europe.

BRCA 2021 Symposium, 2021

 

M. P. Lux, A. Niyazov, K. Lewis, L. Massey, A. Rider, B. Arondekar, R. Mahtani

Frequency of Oncologists (ONC) Office Visit and Caregiver Burden with Poly(ADP-ribose) Polymerase Inhibitor (PARPi) Versus Chemotherapy (CTX) Among Adult Patients (pts) with germline BRCA1/2 Mutated (gBRCA1/2mut) HER2- Advanced Breast Cancer (ABC): Results from a Multi-country Real World (RW) Study.

NCCN 2021 Virtual Annual Conference, 2021

 

R. Mahtani, A. Niyazov, K. Lewis, L. Massey, A. Rider, B. Arondekar, M. P. Lux

Real-world Study of BRCA1/2 Mutation (BRCA1/2mut) Testing Among Adult Patients (Pts) with HER2− Advanced Breast Cancer (ABC) in the US.

NCCN 2021 Virtual Annual Conference, 2021


Originalarbeiten mit Erst- oder Letztautorenschaft

K. Hübel, F. Kron, M. P. Lux

Biosimilars in Oncology: Effects on Economy and Therapeutic Innovations.

European Journal of Cancer, 139: 10-19, 2020

 

T. Papathemelis, H. Oppermann, S. Grafl, M. Gerken, A. Pauer, S. Scharl, A. Scharl, E. Inwald, A. Ignatov, O. Ortmann, M. Klinkhammer-Schalke, A. Hein, M. W. Beckmann, M. P. Lux

Long-term outcome of patients with intermediate- and high-risk endometrial cancer after pelvic and paraaortic lymph node dissection: a comparison of laparoscopic vs. open procedure.

J Cancer Res Clin Oncol, 146(4): 961-969, 2020

 

M. P. Lux, T. Decker, E. D. Runkel, A. Niyazov, R. G. W. Queke, N. Marschner, N. Harbeck

Awareness and Availability of Routine Germline BRCA1/2 Mutation Testing in Patients With Advanced Breast Cancer in Germany.

Breast care, 2020 

 

S. M. Jud, A. Brendle-Behnisch, C. Rauh, M. G. Schrauder, C. C. Hack, A.-L. Brandl, S. Wasner, C. Preuß, M. W. Beckmann, M. P. Lux  

Macromastia – an economic burden? A disease cost analysis based on real world data in Germany.

Archives of Gynecology and Obstetrics, 2020

doi: 10.1007/s00404-020-05841-7. Online ahead of print. 

 

M. P. Lux, S. Wasner, J. Meyer, L. Häberle, C. C. Hack, S. Jud, A. Hein, M. Wunderle, J. Emons, P. Gaß, P. A. Fasching, S. Egloffstein, J. Krebs, Y. Erim, M. W. Beckmann, C. R. Loehberg

Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center Regarding Consensus between the First and Second Opinion and Conformity with the Guidelines.

Breast Care (DOI:10.1159/000509127), 2020 

 

M. P. Lux, A. Brendle-Behnisch, C. C. Hack, C. Preuß, A. Arkudas, R. E. Horch, M. W. Beckmann, S. M. Jud

Is the Reduction Mammoplasty cost-effective?

Cost-Utility-Analysis of Surgical Treatment of Macromastia in Germany. 

Breast Care (in revision), 2020

 

M. P. Lux, K. Lewis, A. Rider, A. Niyazov 

BRCA1/2 Mutation Testing Among Adult Women With HER2- Advanced Breast Cancer: Results From a Multi-Country, Real-World Study. 

Journal of Global Oncology (submitted), 2020

 

Originalarbeiten mit Co-Autorenschaft

H. Huebner, C. M. Kurbacher, G. Kuesters, A. D. Hartkopf, M. P. Lux, J. Huober, B. Volz, F.-A. Taran, F. Overkamp, H. Tesch, L. Häberle, D. Lüftner, M. Wallwiener, V. Müller, M. W. Beckmann, E. Belleville, M. Ruebner, M. Untch, P. A. Fasching, W. Janni, T. N. Fehm, H. -C. Kolberg, D. Wallwiener, S. Y. Brucker, A. Schneeweiss, J. Ettl

Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

BMC Cancer, 20: 1091, 2020 

Published online 2020 Nov 11. doi: 10.1186/s12885-020-07546-1

 

E. Laakmann, J. Emons, F.-A. Taran, W. Janni, S. Uhrig, F. Overkamp, H. -C. Kolberg, P. Hadji, H. Tesch, L. Häberle, J. Ettl, D. Lüftner, M. Wallwiener, C. Schulmeyer, V. Müller, M. W. Beckmann, E. Belleville, P. Wimberger, C. Hielscher, C. Kurbacher, R. Wuerstlein, C. Thomssen, M. Untch, B. Volz, P. A. Fasching, T. N. Fehm, D. Wallwiener, S. Y. Brucker, A. Schneeweiss, M. P. Lux, A. D. Hartkopf

Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. 

Geburtshilfe Frauenheilkd, 80 (11): e289, 2020

Published online 2020 Nov 25. doi: 10.1055/a-1306-7231

 

A. Schneeweiss, J. Ettl, D. Lüftner, M. W. Beckmann, E. Belleville, P. A. Fasching, T. N. Fehm, M. Geberth, L. Häberle, P. Hadji, A. D. Hartkopf, C. Hielscher, J. Huober, E. Ruckhäberle, W. Janni, H. C. Kolberg, C. M. Kurbacher, E. Klein, M. P. Lux, V. Müller, N. Nabieva, F. Overkamp, H. Tesch, E. Laakmann, F. A. Taran, J. Seitz, C. Thomssen, M. Untch, P. Wimberger, R. Wuerstlein, B. Volz, D. Wallwiener, M. Wallwiener, S. Y. Brucker

Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.

Breast, 54: 88-95, 2020

doi: 10.1016/j.breast.2020.08.011. Online ahead of print.

 

C. C. Hack, L. Häberle, S. Y. Brucker, W. Janni, B. Volz, C. R. Loehberg, A. D. Hartkopf, C. B. Walter, G. Baake, A. Fridman, W. Malter, R. Wuerstlein, N. Harbeck, O. Hoffmann, S. Kuemmel, B. Martin, C. Thomssen, H. Graf, C. Wolf, M. P. Lux, C. M. Bayer, C. Rauh, K. Almstedt, P. Gass, F. Heindl, T. Brodkorb, L. Willer, C. Lindner, H. C. Kolberg, P. Krabisch, M. Weigel, D. Steinfeld-Birg, A. Kohls, C. Brucker, V. Schulz, G. Fischer, V. Pelzer, R. Rack, M. W. Beckmann, T. Fehm, A. Rody, N. Maass, A. Hein, P. A. Fasching, N. Nabieva

Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients.

Breast, 50: 11-18, 2020

doi: 10.1016/j.breast.2019.12.017. Epub 2020 Jan 8.

 

M. Wunderle, M. Ruebner, L. Häberle, E. Schwenke, C. C. Hack, C. M. Bayer, M. C. Koch, J. Schwitulla, R. Schulz-Wendtland, I. Kozieradzki, M. Lux, M. W. Beckmann, S. M. Jud, J. M. Penninger, M. O. Schneider, P. A. Fasching

RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women.

Sci Rep, 10(1): 5171, 2020 

doi: 10.1038/s41598-020-62070-3.

 

C. C. Hack, S. Wasner, J. Meyer, L. Häberle, S. Jud, A. Hein, M. Wunderle, J. Emons, P. Gass, P. A. Fasching, S. Egloffstein, M. W. Beckmann, M. P. Lux, C. R. Loehberg

Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center in Relation to Complementary and Alternative Medicine.

Complement Med Res, 16:1-9, 2020

doi: 10.1159/000508235. Online ahead of print. PMID: 32544918

 

C. R. Loehberg, J. Meyer, L. Häberle, C. C. Hack, S. Jud, A. Hein, M. Wunderle, J. Emons, P. Gass, P. A. Fasching, , S. Egloffstein, J. Krebs, Y. Erim, M. W. Beckmann, M. P. Lux, S. Wasner

Analysis of motives and patient satisfaction in oncological second opinions provided by a certified university breast and gynecological cancer center.

Arch Gynecol Obstet, 301(5): 1299-1306, 2020 

doi: 10.1007/s00404-020-05525-2. Epub 2020 Apr 9. PMID: 32274639

 

A. Schneeweiss, J. Ettl, D. Lüftner, M. W. Beckmann, E. Belleville, P. A. Fasching, T. N. Fehm, M. Geberth, L. Häberle, P. Hadji, A. D. Hartkopf, C. Hielscher, J. Huober, E. Ruckhäberle, W. Janni, H. C. Kolberg, C. M. Kurbacher, E. Klein, M. P. Lux, V. Müller, N. Nabieva, F. Overkamp, H. Tesch, E. Laakmann, F.-A. Taran, J. Seitz, C. Thomssen, M. Untch, P. Wimberger, R. Wuerstlein, B. Volz, D. Wallwiener, M. Wallwiener, S. Y. Brucker

Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.

The Breast, 54: 88-95, 2020

 

L. Michel, A. D. Hartkopf, P. A. Fasching, H.-C. Kolberg, P. Hadji, H. Tesch, L. Haeberle, J. Ettl, D. Lüftner, M. Wallwiener, V. Müller, M. W. Beckmann , E. Belleville, B. Volz, H. Huebner, P. Wimberger, C. Hielscher, C. Mundhenke, C. Kurbacher, R. Wuerstlein, M. Untsch, F. Overkamp, J. Huober, W., F.-A. Taran, M. P. Lux, D. Wallwiener, S. Y. Brucker, A. Schneeweiss, T. N. Fehm

Progression-free survival and overall survival in patients with advanced HER2-positive breast cancer treated with trastuzumab emtansine (T-DM1) after previous treatment with pertuzumab.

Cancers, 12(19): 1299-1306, 2020

 

M. Wunderle, L. Häberle, A. Hein, S. M. Jud, M. P. Lux, C. C. Hack, J. Emons, F. Heindl, N. Nabieva, C. R. Loehberg, R. Schulz-Wendtland, A. Hartmann, M. W. Beckmann, P. A. Fasching, P. Gass

Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.

Breast Care, doi.org/10.1159/000507475, 2020

 

A. K. Dippmann, C. Damrau, J. Hengelbrock, U.-S. Albert, A. Lebeau, M. P. Lux, C. Veit

Are men and women with breast cancer treated equally in Germany?

Z Evid Fortbild Qual Gesundh wesen (ZEFQ), 155: 1-10, 2020

 

Übersichtsarbeiten

M. P. Lux

Biomarkertest-basierte Therapieentscheidung beim primären Mammakarzinom. 

Refresher Onkologie, 2020

 

M. P. Lux, A. Schneeweiss, A. D. Hartkopf, V. Müller, W. Janni, E. Belleville, E. Stickeler, M. Thill, P. A. Fasching, H.-C. Kolberg, M. Untch, N. Harbeck, A. Wöckel, C. Thomssen, C. E. Schulmeyer, M. Welslau, F. Overkamp, F. Schütz, D. Lüftner, N. Ditsch

Update Breast Cancer 2020 – Part V – Moving therapies from advanced to early breast cancer patients.

Geburtshilfe Frauenheilk, 2020 (in press)

 

A. Schneeweiss I. Bauerfeind, T. Fehm, W.  Janni, C. Thomssen, I. Witzel, A. Wöckel, V. Müller, on behalf of the Commission Breast of the Working Group Gynecologic Oncology (AGO)

Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer.

Breast Care, 15: 608-618, 2020

DOI: 10.1159/000511925

 

D. Lüftner, A. Schneeweiss, A. D. Hartkopf, V. Müller, A. Wöckel, W. Janni, J. Ettl, E. Belleville, F. Schütz, M. Thill, J. Huober, P. A. Fasching, H.-C. Kolberg, P. Pöschke, M. Welslau, F. Overkamp, H. Tesch, T. N. Fehm, M. P. Lux

Update Mammakarzinom 2020. Teil 2 – fortgeschrittenes Mammakarzinom: neue Substanzen und Einzug diagnostikabhängiger Therapien.

Senologie, 17: 163-171, 2020

 

D. Lüftner, A. Schneeweiss, A. D. Hartkopf, V. Müller, A. Wöckel, W. Janni, J. Ettl, E. Belleville, F. Schütz, M. Thill, J. Huober, P. A. Fasching, H.-C. Kolberg, P. Pöschke, M. Welslau, F. Overkamp, H. Tesch, T. N. Fehm, M. P. Lux

Update Mammakarzinom 2020. Teil 2 – fortgeschrittenes Mammakarzinom: neue Substanzen und Einzug diagnostikabhängiger Therapien.

Geburtshilfe Frauenheilk, 80 (4): 391-398, 2020

 

C. Kowalski, U.S. Albert, W. Baumann, E.-G. Carl, N. Ernstmann, K. Hermes-Moll, E. M. Fallenberg, G. Feiten, M. Härter, V. Heidt, C. Heuser, J. Hübner, S. Joos, A. Katalinic, Ö. Kempkens, H. Kerek-Bodden, M. Klinkhammer-Schalke, M. Koller, T. Langer, B. Lehner, M. P. Lux, I. Maatouk, H. Pfaff, B. Ratsch, S. Schach, I. Scholl, N. Skoetz, R. Voltz, J. Wiskemann, E. Inwald

DNVF Memorandum Health Services Research in Oncology. 

Gesundheitswesen, 82 (8-09): e108-e121, 2020, DOI 10.1055/a-1191-3759

 

J. Huober, A. Schneeweiss, A. D. Hartkopf, V. Müller, M. P. Lux, W. Janni, J. Ettl, E. Belleville, M. Thill, P. A. Fasching, H. C. Kolberg, C. E. Schulmeyer, M. Welslau, F. Overkamp, H. Tesch, T. N. Fehm, D. Lüftner, F. Schütz, A. Wöckel

Update Breast Cancer 2020 – Part III – Early breast cancer.

Geburtshilfe Frauenheilkd, 80 (11): 1105–1114, 2020

Published online 2020 Nov 6. doi: 10.1055/a-1270-7208

 

H. Tesch, V. Müller, A. Wöckel, J. Ettl, E. Belleville, F. Schütz, A. Hartkopf, M. Thill, J. Huober, P. A. Fasching, H. C. Kolberg, C. E. Schulmeyer, M. Welslau, F. Overkamp, T. N. Fehm, M. P. Lux, A. Schneeweiss, D. Lüftner, W. Janni

Update Breast Cancer 2020 Part IV – Advanced breast cancer.

Geburtshilfe Frauenheilkd, 80 (11): 1115–1122, 2020 

Published online 2020 Nov 6. doi: 10.1055/a-1270-7481

 

A. Schneeweiss, A. D. Hartkopf, V. Müller, A. Wöckel, M. P. Lux, W. Janni, J. Ettl, E. Belleville, J. Huober, M. Thill, P. A. Fasching, H.-C. Kolberg, P. Pöschke, M. Welslau, F. Overkamp, H. Tesch, T. N. Fehm, D. Lüftner, F. Schütz

Update Mammakarzinom 2020. Teil 1 – frühes Mammakarzinom: Konsolidierung des Wissens über bekannte Therapien.

Senologie, 17: 94-104, 2020

A. Schneeweiss, A. D. Hartkopf, V. Müller, A. Wöckel, M. P. Lux, W. Janni, J. Ettl, E. Belleville, J. Huober, M. Thill, P. A. Fasching, H.-C. Kolberg, P. Pöschke, M. Welslau, F. Overkamp, H. Tesch, T. N. Fehm, D. Lüftner, F. Schütz

Update Mammakarzinom 2020. Teil 1 – frühes Mammakarzinom: Konsolidierung des Wissens über bekannte Therapien.

Geburtshilfe Frauenheilk, 80 (3): 277-287, 2020

 

N. Ditsch, M. Untch, C. Kolberg-Liedtke, C. Jackisch, D. Krug, M. Friedrich, W. Janni, V. Müller, U.-S. Albert, M. Banys-Paluchowski, I. Bauerfeind, J.-U. Blohmer, W. Budach, P. Dall, I. Diel, E. M. Fallenberg, P. A. Fasching, T. Fehm, B. Gerber, O. Gluz, V. Hanf, N. Harbeck, J. Heil, J. Huober, H. H. Kreipe, D. Krug, T. Kühn, S. Kümmel, S. Loibl, D. Lüftner, M. P. Lux, N. Maass, V. Möbus, C. Mundhenke, T.-W. Park-Simon, T. Reimer, K. Rhiem, A. Rody, M. Schmidt, A. Schneeweiss, C. Solbach, E. F. Solomayer, E. Stickeler, C. Thomssen, I. Witzel, A. Wöckel, M. Thill

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020.

Breast Care (Basel), 15: 294.309, 2020

 

A. D. Hartkopf, V. Müller, A. Wöckel, M. P. Lux, W. Janni, J. Ettl, E. Belleville, F. Schütz, P. A. Fasching, H. C. Kolberg, M. Weslau, F. Overkamp, F. A. Taran, S. Y. Brucker, M. Wallwiener, H. Tesch, T. N. Fehm, A. Schneeweiss, D. Lüftner

Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/5 Therapy.

Senologie, 17: 31-41, 2020

 

Buchkapitel/ Bücher

M. P. Lux, D. Lüftner, D. T. Schneider

Late Effects in Young Breast Cancer Survivor.

In J. D. Beck, C. Bokemeyer, T. Langer 

Late Treatment Effects and Cancer Survivor Care in the Young.

Springer, 2021, pp 357-364 

 

Sonstige Artikel

C. Schmücker

Ängste, Aufregung – und am Ende Stolz. 

Hebammenforum, 21, 2020

 

Abstracts & Poster

M. P. Lux, A. Niyazov, K. Lewis, J. Pike, A. Rider, B. Arondekar, R. Mahtani

Physician and Patient Satisfaction with Poly(ADPribose) Polymerase Inhibitors (PARPi) versus Chemotherapy in Adult Patients with Germline BRCA1/2 Mutated ( gBRCA1/2 mut) HER2 Advanced Breast Cancer (ABC): Results from a Multi Country Real World (RW) Study.

San Antonio Breast Cancer Symposium: PS10-47, 2020

 

R. Mahtani, A. Niyazov, K. Lewis, J. Pike, A. Rider, B. Arondekar, M. P. Lux

Patient Reported Outcomes (PROs) with Poly(ADPribose) polymerase inhibitors (PARPi) versus Chemotherapy (CTX) in Patients (pts) with Germline BRCA 1/2 Mutated (gBRCA1/2 mut) HER2 Advanced Breast Cancer (ABC): Results from a Multi Country Real World (RW) Study.

San Antonio Breast Cancer Symposium: PS10-32, 2020

 

M. P. Lux, L. Brandt, K. H. Herrmann, T. Ecker

Scenarios of Cost-Savings Associated with Oncotype DX Test-Guided Decisions for Adjuvant Chemotherapy in EARLY Breast Cancer in Germany.

ISPOR, 2020

Value in Health, Volume 23, Issue S2, 2020

Certificate of Recognition from ISPOR: recognized within the Top 10% highest average review scores

 

M. P. Lux, M. Thill, E. Runkel, N. Marchner

PERFORM: An Epidemiological, Prospective Cohort Study to Generate Real-world Evidence in Patients with HR+/HER2- Advanced Breast Cancer Treated in the First-line Setting as per Current Standard Of Care With an Endocrine-based Palbociclib Combination Therapy.

DGHO Jahrestagung, 2020

 

H. Huebner, C. M. Kurbacher, G. Kuesters, A. D. Hartkopf, M. P. Lux, J. Huober, B. Volz, F.-A. Taran, F. Overkamp, H. Tesch, L. Häberle, D. Lüftner, M. Wallwiener, V. Müller, M. W. Beckmann, E. Belleville, M. Untch, W. Janni, T. N. Fehm, H. C. Kolberg, D. Wallwiener, S. Y. Brucker, A. Schneeweiss, J. Ettl, M. Rübner, P. A. Fasching

Nutzung eines molekularen Registers (PRAEGNANT) zur Patienten-Selektion und Biomarker-Analyse für die SHERBOC Studie.

DGGG Jahrestagung, 2020 

 

S. Bader, M. Wunderle, L. Häberle, A. Hein, S. M. Jud, M. P. Lux, C. C. Hack, J. Emons, F. Heindl, N. Nabieva, C. R. Loehberg, R. Schulz-Wendtland, A. Hartmann, M. W. Beckmann, P. A. Fasching, P. Gass

Einfluss einer positiven Familienanamnese (für Mamma- oder Ovarialkarzinome) auf die pathologische Komplettremission und die Langzeitprognose bei Brustkrebspatientinnen nach neoadjuvanter Chemotherapie.

DGGG Jahrestagung, 2020 

 

R. Mahtani, A. Niyazov, K. Lewis, J. Pike, A. Rider, B. Arondekar, M. P. Lux

Health Status/Utilities in Adult Patients with Advanced Breast Cancer (ABC) and Germline BRCA1/2 Mutation (gBRCA1/2mut) Treated with Poly(ADP-ribose) polymerase inhibitors (PARPi) Versus Chemotherapy in a Real World (RW) Setting.

ISPOR, 2020

 

M. P. Lux, A. Niyazov, K. Lewis, A. Rider, B. Arondekar, R. Mahtani

Real-world (RW) Multi-country Study of BRCA1/2 Testing in Adult Patients (pts) With HER2- Advanced Breast Cancer (ABC).

ESMO, Poster 3045, 2020#

 

R. Mahtani, A. Niyazov, K. Lewis, M. Last, A. Rider, B. Arondekar, M. P. Lux

Patient Demographics, Treatment Patterns and Hematologic Toxicities Among Patients with HER2– Advanced Breast Cancer (ABC) and BRCA1/2 Mutation(s): A Multi-country Real-world Study.

ESMO BC, Poster Number #669, 2020

 

R. Mahtani, A. Niyazov, K. Lewis, R. Wild, A. Rider, B. Arondekar, M. P. Lux 

Germline BRCA1/2 (gBRCA1/2) Testing Patterns Among Oncologists Treating HER2– Advanced Breast Cancer (ABC): Results From a Multi-country Real-world Study.

ESMO BC, Poster Number #400, 2020

 

M. P. Lux, T. Decker, E. D. Runkel, A. Niyazov, R. G. W. Quek, E. Glastetter, N. Marschner, N. Harbeck

Awareness and Availability of Routine Germline BRCA1/2 (gBRCA1/2) Mutation Testing in Patients With Advanced Breast Cancer in Germany.

ESMO BC, 2020


M. G. Schrauder, L. Brunel-Geuder, L. Häberle, M. Wunderle, J. Hoyer, R. Csorba, A. Reis, R. Schulz-Wendtland, M. W. Beckmann, M. P. Lux

Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy.

Eur J Med Res, 24(1): 32, 2019

 

M. P. Lux, S. Böhme, S. Hücherig, U. Jeratsch, N. Kürschner, D. Lüftner

Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer.

Breast Cancer Res Treat, 176(3): 495-506, 2019

 

M. P. Lux, J. Emons, M. R. Bani, M. Wunderle, C. Sell, C. Preuss, C. Rauh, S. M. Jud, F. Heindl, H. Langemann, T. Geyer, A. L. Brandl, C. C. Hack, W. Adler, R. Schulz-Wendtland, M. W. Beckmann, P. A. Fasching, P. Gass

Diagnostic Accuracy of Breast Medical Tactile Examiners (MTEs): A Prospective Pilot Study.

Breast Care (Basel), 14 (1): 41-47, 2019

 

T. Hildebrandt, N. Oversohl, R. Dittrich, L. Lotz, M. W. Beckmann, M. P. Lux

Can a University Reproductive Medicine Centre Be Financed Under the Pre-Existing General Conditions in Germany?

Geburtshilfe Frauenheilkd, 79 (1): 63-71, 2019

 

U. G. Poehls, C. C. Hack, M. Wunderle, S. P. Renner, M. P. Lux, M. W. Beckmann, P. A. Fasching, N. Nabieva

Awareness of breast cancer incidence and risk factors among healthy women in Germany: an update after 10 years.

Eur J Cancer Prev, 28(6): 515-521, 2019

 

L. M. Matthies, F. A. Taran, L. Keilmann, A. Schneeweiss, E. Simoes, A. D. Hartkopf, A. N. Sokolov, C. B. Walter, N. Sickenberger, S. Wallwiener, M. Feisst, P. Gass, M. P. Lux, F. Schuetz, P. A. Fasching, C. Sohn, S. Y. Brucker, J. Graf, M. Wallwiener

An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study.

J Med Internet Res, 21(1): e10004, 2019

 

J. Heil, F. Riedel, C. Solbach, B. Gerber, M. Marx, S. Brucker, C. Heitmann, J. Hoffmann, M. Wallwiener, M. P. Lux, D. Wallwiener, M. Hahn

Oncoplastic breast-conserving surgery: More relevant than ever? Results of a survey among breast

surgeons.

Arch Gynecol Obstet, 299 (4): 1109-1114, 2019

 

M. Wunderle, J. Pretscher, S. Y. Brucker, B. Volz, A. Hartmann, C. Fiessler, A. Hein, L. Häberle, S. M. Jud, M. P. Lux, W. Janni, C. R. Loehberg, A. D. Hartkopf, C. B. Walter, G. Baake, A. Fridman, W. Malter, R. Wuerstlein, N. Harbeck, O. Hoffmann, S. Kümmel, B. Martin, C. Thomssen, H. Graf, C. Wolf, C. M. Bayer, C. C. Hack, K. Almstedt, P. Gass, F. Heindl, T. F. Brodkorb, N. Nabieva, C. Lindner, H. C. Kolberg, P. Krabisch, M. Weigel, D. Steinfeld-Birg, A. Kohls, C. Brucker, V. Schulz, G. Fischer, V. Pelzer, D. Wallwiener, B. Rack, T. Fehm, A. Rody, N. Maass, M. W. Beckmann, P. A. Fasching, C. Rauh

Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer.

Breast Cancer Res Treat, 174 (2): 453-461, 2019

 

Escala-Garcia M, Guo Q, Dörk T, Canisius S, Keeman R, Dennis J, Beesley J, Lecarpentier J, Bolla MK, Wang Q, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Auer PL, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Boeckx B, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Brenner H, Brentnall A, Brinton L, Broberg P, Brock IW, Brucker SY, Burwinkel B, Caldas C, Caldés T, Campa D, Canzian F, Carracedo A, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Cheng TD, Chin SF, Clarke CL; NBCS Collaborators, Cordina-Duverger E, Couch FJ, Cox DG, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dunn JA, Dunning AM, Durcan L, Dwek M, Earl HM, Ekici AB, Eliassen AH, Ellberg C, Engel C, Eriksson M, Evans DG, Figueroa J, Flesch-Janys D, Flyger H, Gabrielson M, Gago-Dominguez M, Galle E, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, George A, Georgoulias V, Giles GG, Glendon G, Goldgar DE, González-Neira A, Alnæs GIG, Grip M, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Hankinson S, Harkness EF, Harrington PA, Hart SN, Hartikainen JM, Hein A, Hillemanns P, Hiller L, Holleczek B, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huang G, Humphreys K, Hunter DJ, Janni W, John EM, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kabisch M, Kaczmarek K, Kerin MJ, Khan S, Khusnutdinova E, Kiiski JI, Kitahara CM, Knight JA, Ko YD, Koppert LB, Kosma VM, Kraft P, Kristensen VN, Krüger U, Kühl T, Lambrechts D, Le Marchand L, Lee E, Lejbkowicz F, Li L, Lindblom A, Lindström S, Linet M, Lissowska J, Lo WY, Loibl S, Lubiński J, Lux MP, MacInnis RJ, Maierthaler M, Maishman T, Makalic E, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Mavroudis D, McLean C, Meindl A, Middha P, Miller N, Milne RL, Moreno F, Mulligan AM, Mulot C, Nassir R, Neuhausen SL, Newman WT, Nielsen SF, Nordestgaard BG, Norman A, Olsson H, Orr N, Pankratz VS, Park-Simon TW, Perez JIA, Pérez-Barrios C, Peterlongo P, Petridis C, Pinchev M, Prajzendanc K, Prentice R, Presneau N, Prokofieva D, Pylkäs K, Rack B, Radice P, Ramachandran D, Rennert G, Rennert HS, Rhenius V, Romero A, Roylance R, Saloustros E, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schwentner L, Scott RJ, Scott C, Seynaeve C, Shah M, Simard J, Smeets A, Sohn C, Southey MC, Swerdlow AJ, Talhouk A, Tamimi RM, Tapper WJ, Teixeira MR, Tengström M, Terry MB, Thöne K, Tollenaar RAEM, Tomlinson I, Torres D, Truong T, Turman C, Turnbull C, Ulmer HU, Untch M, Vachon C, van Asperen CJ, van den Ouweland AMW, van Veen EM, Wendt C, Whittemore AS, Willett W, Winqvist R, Wolk A, Yang XR, Zhang Y, Easton DF, Fasching PA, Nevanlinna H, Eccles DM, Pharoah PDP, Schmidt MK

Genome-wide association study of germline variants and breast cancer-specific mortality.

Br J Cancer, 120 (6): 647-657, 2019

 

P. A. Fasching, P. Gass, L. Häberle, B. Volz, A. Hein, C. C. Hack, M. P. Lux, S. M. Jud, A. Hartmann, M. W. Beckmann, D. J. Slamon, R. Erber

Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer.

Breast Cancer Res Treat, 175(3): 617-625, 2019

 

M. Sommer, M. Kirchner, C. Gulden, S. Egloffstein, M. P. Lux, M. W. Beckmann, A. Mackensen, H. U. Prokosch

Design and Implementation of a Single Source Multipurpose Hospital-Wide Clinical Trial Registry.

Stud Health Technol Inform, 258: 164-168, 2019

 

N. Nabieva, L. Häberle, S. Y. Brucker, W. Janni, B. Volz, C. R. Loehberg, A. D. Hartkopf, C. B. Walter, G. Baake, A. Fridman, W. Malter, R. Wuerstlein, N. Harbeck, O. Hoffmann, S. Kuemmel, B. Martin, C. Thomssen, H. Graf, C. Wolf, M. P. Lux, C. M. Bayer, C. Rauh, C. C. Hack, K. Almsted, P. Gass, F. Heindl, T. Brodkorb, C. Lindner, H. C. Kolberg, P. Krabisch, M. Weigel, D. Steinfeld-Birg, A. Kohl, C. Brucker, V. Schulz, G. Fischer, V. Pelzer, B. Rack, M. W. Beckmann, T. Fehm, A. Rody, N. Maass, A. Hein, P. A. Fasching

Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients.

Int J Cancer, 145(8): 2114-2121, 2019

 

Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, Wang Q, Bolla MK, Yang X, Adank MA, Ahearn T, Aittomäki K, Allen J, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Auer PL, Auvinen P, Barrdahl M, Beane Freeman LE, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Bremer M, Brenner H, Brentnall A, Brock IW, Brooks-Wilson A, Brucker SY, Brüning T, Burwinkel B, Campa D, Carter BD, Castelao JE, Chanock SJ, Chlebowski R, Christiansen H, Clarke CL, Collée JM, Cordina-Duverger E, Cornelissen S, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dos-Santos-Silva I, Dumont M, Durcan L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Engel C, Eriksson M, Evans DG, Fasching PA, Figueroa J, Fletcher O, Flyger H, Försti A, Fritschi L, Gabrielson M, Gago-Dominguez M, Gapstur SM, García-Sáenz JA, Gaudet MM, Georgoulias V, Giles GG, Gilyazova IR, Glendon G, Goldberg MS, Goldgar DE, González-Neira A, Grenaker Alnæs GI, Grip M, Gronwald J, Grundy A, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hankinson SE, Harkness EF, Hart SN, He W, Hein A, Heyworth J, Hillemanns P, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huang G, Humphreys K, Hunter DJ, Jakimovska M, Jakubowska A, Janni W, John EM, Johnson N, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kaczmarek K, Kataja V, Keeman R, Kerin MJ, Khusnutdinova E, Kiiski JI, Knight JA, Ko YD, Kosma VM, Koutros S, Kristensen VN, Krüger U, Kühl T, Lambrechts D, Le Marchand L, Lee E, Lejbkowicz F, Lilyquist J, Lindblom A, Lindström S, Lissowska J, Lo WY, Loibl S, Long J, Lubiński J, Lux MP, MacInnis RJ, Maishman T, Makalic E, Maleva Kostovska I, Mannermaa A, Manoukian S, Margolin S, Martens JWM, Martinez ME, Mavroudis D, McLean C, Meindl A, Menon U, Middha P, Miller N, Moreno F, Mulligan AM, Mulot C, Muñoz-Garzon VM, Neuhausen SL, Nevanlinna H, Neven P, Newman WG, Nielsen SF, Nordestgaard BG, Norman A, Offit K, Olson JE, Olsson H, Orr N, Pankratz VS, Park-Simon TW, Perez JIA, Pérez-Barrios C, Peterlongo P, Peto J, Pinchev M, Plaseska-Karanfilska D, Polley EC, Prentice R, Presneau N, Prokofyeva D, Purrington K, Pylkäs K, Rack B, Radice P, Rau-Murthy R, Rennert G, Rennert HS, Rhenius V, Robson M, Romero A, Ruddy KJ, Ruebner M, Saloustros E, Sandler DP, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schürmann P, Schwentner L, Scott C, Scott RJ, Seynaeve C, Shah M, Sherman ME, Shrubsole MJ, Shu XO, Slager S, Smeets A, Sohn C, Soucy P, Southey MC, Spinelli JJ, Stegmaier C, Stone J, Swerdlow AJ, Tamimi RM, Tapper WJ, Taylor JA, Terry MB, Thöne K, Tollenaar RAEM, Tomlinson I, Truong T, Tzardi M, Ulmer HU, Untch M, Vachon CM, van Veen EM, Vijai J, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett W, Winqvist R, Wolk A, Yang XR, Yannoukakos D, Zhang Y, Zheng W, Ziogas A; ABCTB Investigators; kConFab/AOCS Investigators; NBCS Collaborators, Dunning AM, Thompson DJ, Chenevix-Trench G, Chang-Claude J, Schmidt MK, Hall P, Milne RL, Pharoah PDP, Antoniou AC, Chatterjee N, Kraft P, García-Closas M, Simard J, Easton DF.

Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes.

Am J Hum Genet, 104 (1): 21-34, 2019

 

H. Tesch, O. Stoetzer, T. Decker, C. M. Kurbacher, F. Marmé, A. Schneeweiss, C. Mundhenke, A. Distelrath, P. A. Fasching, M. P. Lux, D. Lüftner, P. Hadji, W. Janni, M. Muth, J. Kreuzeder, C. Quiering, F. A. Taran

Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.

Int J Cancer, 144 (4): 877-885, 2019

 

M. Wunderle, J. Pretscher, S. Y. Brucker, B. Volz, A. Hartmann, C. Fiessler, A. Hein, L. Häberle, S. M. Jud, M. P. Lux, W. Janni, C. R. Loehberg, A. D. Hartkopf, C. B. Walter, G. Baake, A. Fridman, W. Malter, R. Wuerstlein, N. Harbeck, O. Hoffmann, S. Kümmel, B. Martin, C. Thomssen, H. Graf, C. Wolf, C. M. Bayer, C. C. Hack, K. Almstedt, P. Gass, F. Heindl, T. F. Brodkorb, N. Nabieva, C. Lindner, H. C. Kolberg, P. Krabisch, M. Weigel, D. Steinfeld-Birg, A. Kohls, C. Brucker, V. Schulz, G. Fischer, V. Pelzer, D. Wallwiener, B. Rack, T. Fehm, A. Rody, N. Maass, M. W. Beckmann, P. A. Fasching, C. Rauh

Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer.

Breast Cancer Res Treat, 2019, doi: 10.1007/s10549-018-05115-6 [Epub ahead of print]

 

N. Ditsch, M. Untch, M. Thill, V. Müller, W. Janni, U. S. Albert, I. Bauerfeind, J. Blohmer, W. Budach, P. Dall, I. Diel, P. A. Fasching, T. Fehm, M. Friedrich, B. Gerber, V. Hanf, N. Harbeck, J. Huober, C. Jackisch, C. Kolberg-Liedtke, H. H. Kreipe, D. Krug, T. Kühn, S. Kümmel, S. Loibl, D. Lüftner, M. P. Lux, N. Maass, V. Möbus, M. Müller-Schimpfle, C. Mundhenke, U. Nitz, K. Rhiem, A. Rody, M. Schmidt, A. Schneeweiss, F. Schütz, H. P. Sinn, C. Solbach, E. F. Solomayer, E. Stickeler, C. Thomssen, F. Wenz, I. Witzel, A. Wöckel

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019.

Breast Care (Basel), 14(4): 224-245, 2019

 

M. Thill, C. Jackisch, W. Janni, V. Müller, U. S. Albert, Í. Bauerfeind, J. Blohmer, W. Budach, P. Dall, I. Diel, P. A. Fasching, T. Fehm, M. Friedrich, B. Gerber, V. Hanf, N. Harbeck, J. Huober, C. Kolberg-Liedtke, H. H. Kreipe, D. Krug, T. Kühn, S. Kümmel, S. Loibl, D. Lüftner, M. P. Lux, N. Maass, V. Möbus, M. Müller-Schimpfle, C. Mundhenke, U. Nitz, K. Rhiem, A. Rody, M. Schmidt, A. Schneeweiss, F. Schütz, H. P. Sinn, C. Solbach, E. F. Solomayer, E. Stickeler, C. Thomssen, M. Untch, F. Wenz, I. Witzel, A. Wöckel, N. Ditsch

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019.

Breast Care (Basel), 14(4): 247-255, 2019

 

M. Welslau, A. D. Hartkopf, V. Müller, A. Wöckel, M. P. Lux, W. Janni, J, Ettl, D. Lüftner, E. Belleville, F. Schütz, P. A. Fasching, H. C. Kolberg, N. Nabieva, F. Overkamp, F. A. Taran, S. Y. Brucker, M. Wallwiener, H. Tesch, A. Schneeweiss, T. N. Fehm

Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer.

Geburtshilfe Frauenheilk, 79(10): 1090-1099, 2019

 

F. Schütz, P. A. Fasching, M. Welslau, A. D. Hartkopf, A. Wöckel, M. P. Lux, W. Janni, J. Ettl, D. Lüftner, E. Belleville, H. C. Kolberg, F. Overkamp, F. A. Taran, S. Y. Brucker, M. Wallwiener, H. Tesch, T. N. Fehm, A. Schneeweiss, V. Müller

Update Mammakarzinom 2019 Teil 4 – diagnostische und therapeutische Herausforderungen neuer personalisierter Therapien für Patientinnen mit frühem Mammakarzinom.

Senologie, 16: 281 – 291, 2019

 

M. Welslau, A. D. Hartkopf, V. Müller, A. Wöckel, M. P. Lux, W. Janni, J, Ettl, D. Lüftner, E. Belleville, F. Schütz, P. A. Fasching, H. C. Kolberg, N. Nabieva, F. Overkamp, F. A. Taran, S. Y. Brucker, M. Wallwiener, H. Tesch, A. Schneeweiss, T. N. Fehm

Update Mammakarzinom 2019 Teil 5 – diagnostische und therapeutische Herausforderungen neuer personalisierter Therapien für Patientinnen mit fortgeschrittenem Mammakarzinom.

Senologie, 16: 292 – 301, 2019

 

A. D. Hartkopf, V. Müller, A. Wöckel, M. P. Lux, W. Janni, J. Ettl, E. Belleville, F. Schütz, P. A. Fasching, H. C. Kolberg, M. Weslau, F. Overkamp, F. A. Taran, S. Y. Brucker, M. Wallwiener, H. Tesch, T. N. Fehm, A. Schneeweiss, D. Lüftner

Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/5 Therapy.

Geburtshilfe Frauenheilk, 79: 1309 - 1319,2019

 

F. Schütz, P. A.Fasching, M. Welslau, A. D.Hartkopf, A. Wöckel, M. P. Lux, W. Janni, J. Ettl, D. Lüftner, E. Belleville, H.-C. Kolberg, F. Overkamp, F.-A. Taran, S. Y. Brucker, M. Wallwiener, H. Tesch, T. N. Fehm, A. Schneeweiss, V. Müller

Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challanges of New, Personalised Therapies for Patients with Early Breast Cancer.

Geburtshilfe Frauenheilk, 79: 1079-1089, 2019

 

H. C. Kolberg, A. Schneeweiss, T. N. Fehm, A. Wöckel, J. Huober, C. Pontones, A. Titzmann, E. Belleville, M. P. Lux, W. Janni, A. D. Hartkopf, F. A. Taran, M. Wallwiener, F. Overkamp, H. Tesch, J. Ettl, D. Lüftner, V. Müller, F. Schütz, P. A. Fasching, S. Y. Brucker

Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel.

Geburtshilfe Frauenheilkd, 79(5): 470-482, 2019

 

W. Janni, A. Schneeweiss, V. Müller, A. Wöckel, M. P. Lux, A. D. Hartkopf, N. Nabieva, F. A. Taran, H. Tesch, F. Overkamp, D. Lüftner, E. Belleville, F. Schütz, P. A. Fasching, T. N. Fehm, H. C. Kolberg, J. Ettl

Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice.

 

A. D. Hartkopf, V. Müller, A. Wöckel, M. P. Lux, W. Janni, N. Nabieva, F. A. Taran, J. Ettl, D. Lüftner, E. Belleville, F. Schütz, P. A. Fasching, T. N. Fehm, H. C. Kolberg, F. Overkamp, A. Schneeweiss, H. Tesch

Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer.

Geburtshilfe Frauenheilkd, 79 (3): 256-267, 2019

 

M. Wunderle, J. Hoyer, M. P. Lux, P. A. Fasching, M. W. Beckmann

Familiär bedingter Brust- und Eierstockkrebs.

W. Zuckschwerdt Verlag, München, 2019

 

M. P. Lux, K. Lewis, A. Rider, A. Niyazov

BRCA1/2 status, treatment patterns, and safety outcomes in HER2- advanced breast cancer (ABC): Results from the European component of a multi-country real-world study.

San Antonio Breast Cancer Symposium: P2-15-02, 2019

 

M. P. Lux, K. Lewis, A. Rider, A. Niyazov

BRCA1/2 status, treatment patterns and safety outcomes in HER2- advanced breast cancer (ABC): Results from a US real-world study.

San Antonio Breast Cancer Symposium: P2-15-06, 2019

 

M. P. Lux, K. Lewis, A. Rider, A. Niyazov

BRCA1/2 testing in adult women with HER2- advanced breast cancer (ABC): Results from a US real world study

San Antonio Breast Cancer Symposium: P6-08-09, 2019

 

M. P. Lux, K. Lewis, A. Rider, A. Niyazov

Physician practice settings and BRCA1/2 testing rates in HER2- advanced breast cancer (ABC): Results from the European component of a multi-country real-world study.

San Antonio Breast Cancer Symposium: P6-08-10, 2019

 

A. M. Brendle-Behnisch, A. Arkudas, S. M. Jud, M. G. Schrauder, M. R. Bani, C. Rauh, C. C. Hack, R. E. Horch, M. W. Beckmannn, M. P. Lux

Langfristige Kosteneffektivität der Mammareduktionsplastik bei Patientinnen mit Makromastie aus Sicht der Kostenträger und der Gesellschaft.

Senologie, 16 (02): e4-e5, 2019

 

M. Wunderle, M. Rübner, L. Häberle, E. Schwenke, C. C. Hack, C. M. Bayer, M. C. Koch, J. Schwitulla, R. Schulz-Wendtland, I. Kozieradzki, M. P. Lux, M. W. Beckmann, S. M. Jud, J. M. Penninger, M. O. Schneider, P. A. Fasching

RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women.M. G. Schrauder, L. Brunel-Geuder, L. Häberle, M. Wunderle, J. Hoyer, R. Csorba, A. Reis, R. Schulz-Wendtland, M. W. Beckmann, M. P. Lux

Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy.

Eur J Med Res, 24(1): 32, 2019

 

M. P. Lux, S. Böhme, S. Hücherig, U. Jeratsch, N. Kürschner, D. Lüftner

Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer.

Breast Cancer Res Treat, 176(3): 495-506, 2019

 

M. P. Lux, J. Emons, M. R. Bani, M. Wunderle, C. Sell, C. Preuss, C. Rauh, S. M. Jud, F. Heindl, H. Langemann, T. Geyer, A. L. Brandl, C. C. Hack, W. Adler, R. Schulz-Wendtland, M. W. Beckmann, P. A. Fasching, P. Gass

Diagnostic Accuracy of Breast Medical Tactile Examiners (MTEs): A Prospective Pilot Study.

Breast Care (Basel), 14 (1): 41-47, 2019

 

T. Hildebrandt, N. Oversohl, R. Dittrich, L. Lotz, M. W. Beckmann, M. P. Lux

Can a University Reproductive Medicine Centre Be Financed Under the Pre-Existing General Conditions in Germany?

Geburtshilfe Frauenheilkd, 79 (1): 63-71, 2019

 

U. G. Poehls, C. C. Hack, M. Wunderle, S. P. Renner, M. P. Lux, M. W. Beckmann, P. A. Fasching, N. Nabieva

Awareness of breast cancer incidence and risk factors among healthy women in Germany: an update after 10 years.

Eur J Cancer Prev, 28(6): 515-521, 2019

 

L. M. Matthies, F. A. Taran, L. Keilmann, A. Schneeweiss, E. Simoes, A. D. Hartkopf, A. N. Sokolov, C. B. Walter, N. Sickenberger, S. Wallwiener, M. Feisst, P. Gass, M. P. Lux, F. Schuetz, P. A. Fasching, C. Sohn, S. Y. Brucker, J. Graf, M. Wallwiener

An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study.

J Med Internet Res, 21(1): e10004, 2019

 

J. Heil, F. Riedel, C. Solbach, B. Gerber, M. Marx, S. Brucker, C. Heitmann, J. Hoffmann, M. Wallwiener, M. P. Lux, D. Wallwiener, M. Hahn

Oncoplastic breast-conserving surgery: More relevant than ever? Results of a survey among breast

surgeons.

Arch Gynecol Obstet, 299 (4): 1109-1114, 2019

 

M. Wunderle, J. Pretscher, S. Y. Brucker, B. Volz, A. Hartmann, C. Fiessler, A. Hein, L. Häberle, S. M. Jud, M. P. Lux, W. Janni, C. R. Loehberg, A. D. Hartkopf, C. B. Walter, G. Baake, A. Fridman, W. Malter, R. Wuerstlein, N. Harbeck, O. Hoffmann, S. Kümmel, B. Martin, C. Thomssen, H. Graf, C. Wolf, C. M. Bayer, C. C. Hack, K. Almstedt, P. Gass, F. Heindl, T. F. Brodkorb, N. Nabieva, C. Lindner, H. C. Kolberg, P. Krabisch, M. Weigel, D. Steinfeld-Birg, A. Kohls, C. Brucker, V. Schulz, G. Fischer, V. Pelzer, D. Wallwiener, B. Rack, T. Fehm, A. Rody, N. Maass, M. W. Beckmann, P. A. Fasching, C. Rauh

Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer.

Breast Cancer Res Treat, 174 (2): 453-461, 2019

 

Escala-Garcia M, Guo Q, Dörk T, Canisius S, Keeman R, Dennis J, Beesley J, Lecarpentier J, Bolla MK, Wang Q, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Auer PL, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Boeckx B, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Brenner H, Brentnall A, Brinton L, Broberg P, Brock IW, Brucker SY, Burwinkel B, Caldas C, Caldés T, Campa D, Canzian F, Carracedo A, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Cheng TD, Chin SF, Clarke CL; NBCS Collaborators, Cordina-Duverger E, Couch FJ, Cox DG, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dunn JA, Dunning AM, Durcan L, Dwek M, Earl HM, Ekici AB, Eliassen AH, Ellberg C, Engel C, Eriksson M, Evans DG, Figueroa J, Flesch-Janys D, Flyger H, Gabrielson M, Gago-Dominguez M, Galle E, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, George A, Georgoulias V, Giles GG, Glendon G, Goldgar DE, González-Neira A, Alnæs GIG, Grip M, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Hankinson S, Harkness EF, Harrington PA, Hart SN, Hartikainen JM, Hein A, Hillemanns P, Hiller L, Holleczek B, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huang G, Humphreys K, Hunter DJ, Janni W, John EM, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kabisch M, Kaczmarek K, Kerin MJ, Khan S, Khusnutdinova E, Kiiski JI, Kitahara CM, Knight JA, Ko YD, Koppert LB, Kosma VM, Kraft P, Kristensen VN, Krüger U, Kühl T, Lambrechts D, Le Marchand L, Lee E, Lejbkowicz F, Li L, Lindblom A, Lindström S, Linet M, Lissowska J, Lo WY, Loibl S, Lubiński J, Lux MP, MacInnis RJ, Maierthaler M, Maishman T, Makalic E, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Mavroudis D, McLean C, Meindl A, Middha P, Miller N, Milne RL, Moreno F, Mulligan AM, Mulot C, Nassir R, Neuhausen SL, Newman WT, Nielsen SF, Nordestgaard BG, Norman A, Olsson H, Orr N, Pankratz VS, Park-Simon TW, Perez JIA, Pérez-Barrios C, Peterlongo P, Petridis C, Pinchev M, Prajzendanc K, Prentice R, Presneau N, Prokofieva D, Pylkäs K, Rack B, Radice P, Ramachandran D, Rennert G, Rennert HS, Rhenius V, Romero A, Roylance R, Saloustros E, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schwentner L, Scott RJ, Scott C, Seynaeve C, Shah M, Simard J, Smeets A, Sohn C, Southey MC, Swerdlow AJ, Talhouk A, Tamimi RM, Tapper WJ, Teixeira MR, Tengström M, Terry MB, Thöne K, Tollenaar RAEM, Tomlinson I, Torres D, Truong T, Turman C, Turnbull C, Ulmer HU, Untch M, Vachon C, van Asperen CJ, van den Ouweland AMW, van Veen EM, Wendt C, Whittemore AS, Willett W, Winqvist R, Wolk A, Yang XR, Zhang Y, Easton DF, Fasching PA, Nevanlinna H, Eccles DM, Pharoah PDP, Schmidt MK

Genome-wide association study of germline variants and breast cancer-specific mortality.

Br J Cancer, 120 (6): 647-657, 2019

 

P. A. Fasching, P. Gass, L. Häberle, B. Volz, A. Hein, C. C. Hack, M. P. Lux, S. M. Jud, A. Hartmann, M. W. Beckmann, D. J. Slamon, R. Erber

Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer.

Breast Cancer Res Treat, 175(3): 617-625, 2019

 

M. Sommer, M. Kirchner, C. Gulden, S. Egloffstein, M. P. Lux, M. W. Beckmann, A. Mackensen, H. U. Prokosch

Design and Implementation of a Single Source Multipurpose Hospital-Wide Clinical Trial Registry.

Stud Health Technol Inform, 258: 164-168, 2019

 

N. Nabieva, L. Häberle, S. Y. Brucker, W. Janni, B. Volz, C. R. Loehberg, A. D. Hartkopf, C. B. Walter, G. Baake, A. Fridman, W. Malter, R. Wuerstlein, N. Harbeck, O. Hoffmann, S. Kuemmel, B. Martin, C. Thomssen, H. Graf, C. Wolf, M. P. Lux, C. M. Bayer, C. Rauh, C. C. Hack, K. Almsted, P. Gass, F. Heindl, T. Brodkorb, C. Lindner, H. C. Kolberg, P. Krabisch, M. Weigel, D. Steinfeld-Birg, A. Kohl, C. Brucker, V. Schulz, G. Fischer, V. Pelzer, B. Rack, M. W. Beckmann, T. Fehm, A. Rody, N. Maass, A. Hein, P. A. Fasching

Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients.

Int J Cancer, 145(8): 2114-2121, 2019

 

Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, Wang Q, Bolla MK, Yang X, Adank MA, Ahearn T, Aittomäki K, Allen J, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Auer PL, Auvinen P, Barrdahl M, Beane Freeman LE, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Bremer M, Brenner H, Brentnall A, Brock IW, Brooks-Wilson A, Brucker SY, Brüning T, Burwinkel B, Campa D, Carter BD, Castelao JE, Chanock SJ, Chlebowski R, Christiansen H, Clarke CL, Collée JM, Cordina-Duverger E, Cornelissen S, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dos-Santos-Silva I, Dumont M, Durcan L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Engel C, Eriksson M, Evans DG, Fasching PA, Figueroa J, Fletcher O, Flyger H, Försti A, Fritschi L, Gabrielson M, Gago-Dominguez M, Gapstur SM, García-Sáenz JA, Gaudet MM, Georgoulias V, Giles GG, Gilyazova IR, Glendon G, Goldberg MS, Goldgar DE, González-Neira A, Grenaker Alnæs GI, Grip M, Gronwald J, Grundy A, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hankinson SE, Harkness EF, Hart SN, He W, Hein A, Heyworth J, Hillemanns P, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huang G, Humphreys K, Hunter DJ, Jakimovska M, Jakubowska A, Janni W, John EM, Johnson N, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kaczmarek K, Kataja V, Keeman R, Kerin MJ, Khusnutdinova E, Kiiski JI, Knight JA, Ko YD, Kosma VM, Koutros S, Kristensen VN, Krüger U, Kühl T, Lambrechts D, Le Marchand L, Lee E, Lejbkowicz F, Lilyquist J, Lindblom A, Lindström S, Lissowska J, Lo WY, Loibl S, Long J, Lubiński J, Lux MP, MacInnis RJ, Maishman T, Makalic E, Maleva Kostovska I, Mannermaa A, Manoukian S, Margolin S, Martens JWM, Martinez ME, Mavroudis D, McLean C, Meindl A, Menon U, Middha P, Miller N, Moreno F, Mulligan AM, Mulot C, Muñoz-Garzon VM, Neuhausen SL, Nevanlinna H, Neven P, Newman WG, Nielsen SF, Nordestgaard BG, Norman A, Offit K, Olson JE, Olsson H, Orr N, Pankratz VS, Park-Simon TW, Perez JIA, Pérez-Barrios C, Peterlongo P, Peto J, Pinchev M, Plaseska-Karanfilska D, Polley EC, Prentice R, Presneau N, Prokofyeva D, Purrington K, Pylkäs K, Rack B, Radice P, Rau-Murthy R, Rennert G, Rennert HS, Rhenius V, Robson M, Romero A, Ruddy KJ, Ruebner M, Saloustros E, Sandler DP, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schürmann P, Schwentner L, Scott C, Scott RJ, Seynaeve C, Shah M, Sherman ME, Shrubsole MJ, Shu XO, Slager S, Smeets A, Sohn C, Soucy P, Southey MC, Spinelli JJ, Stegmaier C, Stone J, Swerdlow AJ, Tamimi RM, Tapper WJ, Taylor JA, Terry MB, Thöne K, Tollenaar RAEM, Tomlinson I, Truong T, Tzardi M, Ulmer HU, Untch M, Vachon CM, van Veen EM, Vijai J, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett W, Winqvist R, Wolk A, Yang XR, Yannoukakos D, Zhang Y, Zheng W, Ziogas A; ABCTB Investigators; kConFab/AOCS Investigators; NBCS Collaborators, Dunning AM, Thompson DJ, Chenevix-Trench G, Chang-Claude J, Schmidt MK, Hall P, Milne RL, Pharoah PDP, Antoniou AC, Chatterjee N, Kraft P, García-Closas M, Simard J, Easton DF.

Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes.

Am J Hum Genet, 104 (1): 21-34, 2019

 

H. Tesch, O. Stoetzer, T. Decker, C. M. Kurbacher, F. Marmé, A. Schneeweiss, C. Mundhenke, A. Distelrath, P. A. Fasching, M. P. Lux, D. Lüftner, P. Hadji, W. Janni, M. Muth, J. Kreuzeder, C. Quiering, F. A. Taran

Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.

Int J Cancer, 144 (4): 877-885, 2019

 

M. Wunderle, J. Pretscher, S. Y. Brucker, B. Volz, A. Hartmann, C. Fiessler, A. Hein, L. Häberle, S. M. Jud, M. P. Lux, W. Janni, C. R. Loehberg, A. D. Hartkopf, C. B. Walter, G. Baake, A. Fridman, W. Malter, R. Wuerstlein, N. Harbeck, O. Hoffmann, S. Kümmel, B. Martin, C. Thomssen, H. Graf, C. Wolf, C. M. Bayer, C. C. Hack, K. Almstedt, P. Gass, F. Heindl, T. F. Brodkorb, N. Nabieva, C. Lindner, H. C. Kolberg, P. Krabisch, M. Weigel, D. Steinfeld-Birg, A. Kohls, C. Brucker, V. Schulz, G. Fischer, V. Pelzer, D. Wallwiener, B. Rack, T. Fehm, A. Rody, N. Maass, M. W. Beckmann, P. A. Fasching, C. Rauh

Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer.

Breast Cancer Res Treat, 2019, doi: 10.1007/s10549-018-05115-6 [Epub ahead of print]

 

N. Ditsch, M. Untch, M. Thill, V. Müller, W. Janni, U. S. Albert, I. Bauerfeind, J. Blohmer, W. Budach, P. Dall, I. Diel, P. A. Fasching, T. Fehm, M. Friedrich, B. Gerber, V. Hanf, N. Harbeck, J. Huober, C. Jackisch, C. Kolberg-Liedtke, H. H. Kreipe, D. Krug, T. Kühn, S. Kümmel, S. Loibl, D. Lüftner, M. P. Lux, N. Maass, V. Möbus, M. Müller-Schimpfle, C. Mundhenke, U. Nitz, K. Rhiem, A. Rody, M. Schmidt, A. Schneeweiss, F. Schütz, H. P. Sinn, C. Solbach, E. F. Solomayer, E. Stickeler, C. Thomssen, F. Wenz, I. Witzel, A. Wöckel

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019.

Breast Care (Basel), 14(4): 224-245, 2019

 

M. Thill, C. Jackisch, W. Janni, V. Müller, U. S. Albert, Í. Bauerfeind, J. Blohmer, W. Budach, P. Dall, I. Diel, P. A. Fasching, T. Fehm, M. Friedrich, B. Gerber, V. Hanf, N. Harbeck, J. Huober, C. Kolberg-Liedtke, H. H. Kreipe, D. Krug, T. Kühn, S. Kümmel, S. Loibl, D. Lüftner, M. P. Lux, N. Maass, V. Möbus, M. Müller-Schimpfle, C. Mundhenke, U. Nitz, K. Rhiem, A. Rody, M. Schmidt, A. Schneeweiss, F. Schütz, H. P. Sinn, C. Solbach, E. F. Solomayer, E. Stickeler, C. Thomssen, M. Untch, F. Wenz, I. Witzel, A. Wöckel, N. Ditsch

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019.

Breast Care (Basel), 14(4): 247-255, 2019

 

M. Welslau, A. D. Hartkopf, V. Müller, A. Wöckel, M. P. Lux, W. Janni, J, Ettl, D. Lüftner, E. Belleville, F. Schütz, P. A. Fasching, H. C. Kolberg, N. Nabieva, F. Overkamp, F. A. Taran, S. Y. Brucker, M. Wallwiener, H. Tesch, A. Schneeweiss, T. N. Fehm

Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer.

Geburtshilfe Frauenheilk, 79(10): 1090-1099, 2019

 

F. Schütz, P. A. Fasching, M. Welslau, A. D. Hartkopf, A. Wöckel, M. P. Lux, W. Janni, J. Ettl, D. Lüftner, E. Belleville, H. C. Kolberg, F. Overkamp, F. A. Taran, S. Y. Brucker, M. Wallwiener, H. Tesch, T. N. Fehm, A. Schneeweiss, V. Müller

Update Mammakarzinom 2019 Teil 4 – diagnostische und therapeutische Herausforderungen neuer personalisierter Therapien für Patientinnen mit frühem Mammakarzinom.

Senologie, 16: 281 – 291, 2019

 

M. Welslau, A. D. Hartkopf, V. Müller, A. Wöckel, M. P. Lux, W. Janni, J, Ettl, D. Lüftner, E. Belleville, F. Schütz, P. A. Fasching, H. C. Kolberg, N. Nabieva, F. Overkamp, F. A. Taran, S. Y. Brucker, M. Wallwiener, H. Tesch, A. Schneeweiss, T. N. Fehm

Update Mammakarzinom 2019 Teil 5 – diagnostische und therapeutische Herausforderungen neuer personalisierter Therapien für Patientinnen mit fortgeschrittenem Mammakarzinom.

Senologie, 16: 292 – 301, 2019

 

A. D. Hartkopf, V. Müller, A. Wöckel, M. P. Lux, W. Janni, J. Ettl, E. Belleville, F. Schütz, P. A. Fasching, H. C. Kolberg, M. Weslau, F. Overkamp, F. A. Taran, S. Y. Brucker, M. Wallwiener, H. Tesch, T. N. Fehm, A. Schneeweiss, D. Lüftner

Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/5 Therapy.

Geburtshilfe Frauenheilk, 79: 1309 - 1319,2019

 

F. Schütz, P. A.Fasching, M. Welslau, A. D.Hartkopf, A. Wöckel, M. P. Lux, W. Janni, J. Ettl, D. Lüftner, E. Belleville, H.-C. Kolberg, F. Overkamp, F.-A. Taran, S. Y. Brucker, M. Wallwiener, H. Tesch, T. N. Fehm, A. Schneeweiss, V. Müller

Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challanges of New, Personalised Therapies for Patients with Early Breast Cancer.

Geburtshilfe Frauenheilk, 79: 1079-1089, 2019

 

H. C. Kolberg, A. Schneeweiss, T. N. Fehm, A. Wöckel, J. Huober, C. Pontones, A. Titzmann, E. Belleville, M. P. Lux, W. Janni, A. D. Hartkopf, F. A. Taran, M. Wallwiener, F. Overkamp, H. Tesch, J. Ettl, D. Lüftner, V. Müller, F. Schütz, P. A. Fasching, S. Y. Brucker

Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel.

Geburtshilfe Frauenheilkd, 79(5): 470-482, 2019

 

W. Janni, A. Schneeweiss, V. Müller, A. Wöckel, M. P. Lux, A. D. Hartkopf, N. Nabieva, F. A. Taran, H. Tesch, F. Overkamp, D. Lüftner, E. Belleville, F. Schütz, P. A. Fasching, T. N. Fehm, H. C. Kolberg, J. Ettl

Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice.

 

A. D. Hartkopf, V. Müller, A. Wöckel, M. P. Lux, W. Janni, N. Nabieva, F. A. Taran, J. Ettl, D. Lüftner, E. Belleville, F. Schütz, P. A. Fasching, T. N. Fehm, H. C. Kolberg, F. Overkamp, A. Schneeweiss, H. Tesch

Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer.

Geburtshilfe Frauenheilkd, 79 (3): 256-267, 2019

 

M. Wunderle, J. Hoyer, M. P. Lux, P. A. Fasching, M. W. Beckmann

Familiär bedingter Brust- und Eierstockkrebs.

W. Zuckschwerdt Verlag, München, 2019

 

M. P. Lux, K. Lewis, A. Rider, A. Niyazov

BRCA1/2 status, treatment patterns, and safety outcomes in HER2- advanced breast cancer (ABC): Results from the European component of a multi-country real-world study.

San Antonio Breast Cancer Symposium: P2-15-02, 2019

M. P. Lux, K. Lewis, A. Rider, A. Niyazov

BRCA1/2 status, treatment patterns and safety outcomes in HER2- advanced breast cancer (ABC): Results from a US real-world study.

San Antonio Breast Cancer Symposium: P2-15-06, 2019

M. P. Lux, K. Lewis, A. Rider, A. Niyazov

BRCA1/2 testing in adult women with HER2- advanced breast cancer (ABC): Results from a US real world study

San Antonio Breast Cancer Symposium: P6-08-09, 2019

M. P. Lux, K. Lewis, A. Rider, A. Niyazov

Physician practice settings and BRCA1/2 testing rates in HER2- advanced breast cancer (ABC): Results from the European component of a multi-country real-world study.

San Antonio Breast Cancer Symposium: P6-08-10, 2019

A. M. Brendle-Behnisch, A. Arkudas, S. M. Jud, M. G. Schrauder, M. R. Bani, C. Rauh, C. C. Hack, R. E. Horch, M. W. Beckmannn, M. P. Lux

Langfristige Kosteneffektivität der Mammareduktionsplastik bei Patientinnen mit Makromastie aus Sicht der Kostenträger und der Gesellschaft.

Senologie, 16 (02): e4-e5, 2019

M. Wunderle, M. Rübner, L. Häberle, E. Schwenke, C. C. Hack, C. M. Bayer, M. C. Koch, J. Schwitulla, R. Schulz-Wendtland, I. Kozieradzki, M. P. Lux, M. W. Beckmann, S. M. Jud, J. M. Penninger, M. O. Schneider, P. A. Fasching

RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women.

Senologie, 16 (02): e47, 2019

M. P. Lux, K. Lewis, A. Rider, A. Niyazov

BRCA1/2 testing in HER2- advanced breast cancer (ABC): Results from the European component of a multi-country real-world study.

Annals of Oncology, 30 (Sppl. 5): 292P, 2019, mdz241, doi.org/10.1093/annonc/mdz241

Ausgezeichnet mit dem BEST POSTER AWARD der ESMO

 

Gesamtverzeichnis der wissenschaftlichen Veröffentlichungen:

https://www.st-louise.de/fileadmin/user_upload/louise/pdf-downloads/geburtshilfe/Schriftenverzeichnis_Lux_100619.pdf